Major food sources of vitamin D [8].
\r\n\t
",isbn:"978-1-80356-420-3",printIsbn:"978-1-80356-419-7",pdfIsbn:"978-1-80356-421-0",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,isNomenclature:!1,hash:"f188555eee4211fc24b6cca361983149",bookSignature:"Dr. Kim Ho Yeap",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11509.jpg",keywords:"Inductive Coupling, Resonant Inductive Coupling, Magnetic Coupling, Magnetic Resonance, Transmitter, Receiver, Rectenna, Antenna, Induction Coil, Stationery Charging, Dynamic Charging, Rectifier",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"February 25th 2022",dateEndSecondStepPublish:"May 6th 2022",dateEndThirdStepPublish:"July 5th 2022",dateEndFourthStepPublish:"September 23rd 2022",dateEndFifthStepPublish:"November 22nd 2022",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"2 months",secondStepPassed:!0,areRegistrationsClosed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"Dr. Kim Ho Yeap is a senior member of the IEEE, a Chartered Engineer registered with the UK Engineering Council, a Professional Engineer (PEng) registered with the Board of Engineers Malaysia, and an ASEAN Chartered Professional Engineer. In 2008 and 2015 he underwent research attachment at the University of Oxford (UK) and the Nippon Institute of Technology (Japan). Dr. Yeap has been given the university teaching excellence award and 21 research grants. He has published more than 100 research articles.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"126825",title:"Dr.",name:"Kim Ho",middleName:null,surname:"Yeap",slug:"kim-ho-yeap",fullName:"Kim Ho Yeap",profilePictureURL:"https://mts.intechopen.com/storage/users/126825/images/system/126825.jpeg",biography:"Kim Ho Yeap is an associate professor at Universiti Tunku Abdul Rahman, Malaysia. He is an Institute of Electrical and Electronics Engineers (IEEE) senior member, a professional engineer registered with the Board of Engineers, Malaysia, and a chartered engineer registered with the UK Engineering Council. He is the external examiner and external course assessor of Wawasan Open University. From 2017 to 2022, he was editor-in-chief of the Journal on Digital Signal Processing. He has also been a guest editor for the Journal of Applied Environmental and Biological Sciences and Journal of Fundamental and Applied Sciences. He has also been a recipient of the university teaching excellence award and twenty-too research grants. He has published more than 100 research articles in electromagnetics, including refereed journal papers, conference proceedings, books, and book chapters.",institutionString:"Universiti Tunku Abdul Rahman",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Universiti Tunku Abdul Rahman",institutionURL:null,country:{name:"Malaysia"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"11",title:"Engineering",slug:"engineering"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"444315",firstName:"Karla",lastName:"Skuliber",middleName:null,title:"Mrs.",imageUrl:"https://mts.intechopen.com/storage/users/444315/images/20013_n.jpg",email:"karla@intechopen.com",biography:"As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"7617",title:"Electromagnetic Fields and Waves",subtitle:null,isOpenForSubmission:!1,hash:"d87c09ddaa95c04479ffa2579e9f16d2",slug:"electromagnetic-fields-and-waves",bookSignature:"Kim Ho Yeap and Kazuhiro Hirasawa",coverURL:"https://cdn.intechopen.com/books/images_new/7617.jpg",editedByType:"Edited by",editors:[{id:"126825",title:"Dr.",name:"Kim Ho",surname:"Yeap",slug:"kim-ho-yeap",fullName:"Kim Ho Yeap"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10198",title:"Response Surface Methodology in Engineering Science",subtitle:null,isOpenForSubmission:!1,hash:"1942bec30d40572f519327ca7a6d7aae",slug:"response-surface-methodology-in-engineering-science",bookSignature:"Palanikumar Kayaroganam",coverURL:"https://cdn.intechopen.com/books/images_new/10198.jpg",editedByType:"Edited by",editors:[{id:"321730",title:"Prof.",name:"Palanikumar",surname:"Kayaroganam",slug:"palanikumar-kayaroganam",fullName:"Palanikumar Kayaroganam"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"117",title:"Artificial Neural Networks",subtitle:"Methodological Advances and Biomedical Applications",isOpenForSubmission:!1,hash:null,slug:"artificial-neural-networks-methodological-advances-and-biomedical-applications",bookSignature:"Kenji Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/117.jpg",editedByType:"Edited by",editors:[{id:"3095",title:"Prof.",name:"Kenji",surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3828",title:"Application of Nanotechnology in Drug Delivery",subtitle:null,isOpenForSubmission:!1,hash:"51a27e7adbfafcfedb6e9683f209cba4",slug:"application-of-nanotechnology-in-drug-delivery",bookSignature:"Ali Demir Sezer",coverURL:"https://cdn.intechopen.com/books/images_new/3828.jpg",editedByType:"Edited by",editors:[{id:"62389",title:"PhD.",name:"Ali Demir",surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"69654",title:"Nutritional Considerations of Vitamin D Deficiency and Strategies of Food Fortification",doi:"10.5772/intechopen.89612",slug:"nutritional-considerations-of-vitamin-d-deficiency-and-strategies-of-food-fortification",body:'\nHuman body is a complex matrix that requires various components for its healthy functioning. Vitamins and minerals are crucial elements that are often obtained from one’s diet; these are referred to as micronutrients. Most of the latter are not produced by the human body and an unbalanced diet could inevitably lead to various nutrient deficiencies that could pose dramatic health risk for the human body that if severe enough could lead to death. Nutrient deficiency could be a direct effect of the changing eating patterns, but mostly due to poverty and lack of access to proper food especially in low- and middle-income societies. For this reason, studies and research were directed toward fortifying consumed food with vitamins that are most likely to be deficient and their deficiency could pose tremendous health problems. One of the most popular nutritional deficiencies in Lebanon and the Middle East is vitamin D deficiency. Due to the high frequency of vitamin D deficiency in Middle East and Lebanon, it is essential to find a product that is widely consumed among the population and provides a good source of vitamin D regarding its stability. Dairy products are one of the most famous consumed foods in our society, which is why it was chosen to be fortified with vitamin D.
\nHealthy lifestyle improves individual strength, prevents certain illnesses, and maintains an advisable weight. Wellness incorporates physical, emotional, and spiritual well-being (Figure 1). The concept of wellness is not an end point in a person’s life but rather an ongoing lifestyle. Diet and exercise are so linked to each other that they can be considered opposite sides of a coin. An individual’s nourishment is impacted by how much energy is used to perform daily exercises; meanwhile, physical activity directly affects the utilization of supplements in food. Consuming a nutritious diet allows one to progressively perform strenuous exercises for longer durations and prompts an overall better feeling. On the other hand, an imbalanced food intake could lead to inactivity or, in extreme cases, cause severe medical issues [1].
\nFactors contributing to individual wellness [
Our daily consumed foods include bread, rice, dairy products, fruits, vegetables, and meats. Each of them is composed of various nutrients, which are each characterized by its unique chemical composition. Each has its own function; however, they work together to complete body’s functions. Food nutrients are carbohydrates, proteins, fats, vitamins and minerals, and water. Fiber is likewise a fundamental part of our eating routine [2].
\nMacronutrients (carbohydrates, lipids, and proteins) are those that the body requires in huge quantities to give energy and maintain growth, whereas micronutrients including vitamins and minerals are those nutrients required in lesser quantities to help normal health and body functions [1].
\nMacronutrients (carbohydrates, lipids, and proteins) are energy-providing nutrients [1].
Carbohydrates: consist of the three main constituents: carbon, hydrogen, and oxygen. They are made of 3 groups: monosaccharides, disaccharides, and polysaccharides. Monosaccharides are single unit carbs such as glucose. Disaccharides are composed of two sugars connected together. An example of this class is lactose, which is known as milk sugar. Polysaccharides are those formed by more than two sugars and are generally more complex chains such as starch and dextrin [2].
Fats: is an essential part of our body. Fat serves a vital role in protecting the cells and tissues of the essential organs in our body such as brain and heart. Food fats are composed of solid fats, fluid oils, fat-soluble vitamins, and cholesterol. Fats contain oxygen less than carbohydrates. Hence, 1 g of lipids gives the body more energy than carbohydrates (9 Cal/g of fat compared to 4 Cal/g of carbohydrates) [2].
Proteins: are huge natural compounds. Proteins, similar to starches and fats, contain carbon, hydrogen, and oxygen. Likewise, proteins contain around 16% nitrogen, which differentiates them from starches and fats. Proteins are used mainly for growth and development purposes [2].
Nutrients required in little quantities to have healthy and normal body functions are “micronutrients” [1].
Minerals: are inorganic elements that are not broken down by digestion, absorption, or heat. Minerals support with the regulation of body functions and are classified into major and trace minerals [1].
Minerals are needed for body-building; enhancing bones, teeth, and structural parts of soft tissues; muscle contraction; clotting of blood; and nerve stimuli [2].
\nWater represents around 60 percent of the body weight. It is necessary for the use of food materials in the body and for disposal of food excess later on [2].
\nVitamins (natural carbon-containing composites) adjust many of the body’s processes [1]. They are available in small amounts; however, they are essential for physiological functions as growth and development. Vitamins can work as antioxidants, cofactors in metabolic oxidation-reduction responses, and hormones [4].
\nVitamins A, D, E, and K are fat-soluble. They remain inside the fatty parts of foods and are absorbed along with dietary fat. Fat-soluble vitamins have good storage in the body since they are kept in the adipose tissues. Fat-soluble vitamin toxicity symptoms include hair, skin, bones, eye injuries, and anorexia nervosa [1].
\nFat-soluble vitamins include the B vitamin and ascorbic acid (vitamin C). They are distributed in many foods. Water-soluble vitamins are absorbed easily via the enteral tract straight into the blood and then into the cells. Water-soluble vitamins are not stored in large amounts, except vitamin B12. Thus, they should be eaten daily [1].
\nVitamin deficiency is the condition of a long-term lack of a certain vitamin. Most common and serious vitamin deficiencies are as follows [1]:
Vitamin A, which leads to vision defect, impaired growth, and immunity
Vitamin D, which leads to rickets, osteomalacia, or osteoporosis
Vitamin K, which leads to coagulopathy and bone health impacts
Vitamin B12, which leads to pernicious anemia, nerve damage, memory loss, and dementia
Vitamin C, which mainly leads to Scurvy disease, fractures, and depression
Vitamin D, known as the sunshine vitamin, is a real hormone delivered from body’s sterols by the photolytic activity of UV light on the skin [4]. It is a fat-soluble seco-steroid that may be either created within the skin from its precursor (7-dehydrocholesterol) by exposure to sunlight or offered from diet [5, 6]. Vitamin D with calcium, magnesium, and phosphorus plays a crucial role to support bones and teeth health [4].
\nVitamin D can be attained from foods as vitamin D3 (cholecalciferol) or as nutrient D2 (ergocalciferol). D3 is acquired from animal sources, while D2 is available in parasites and mushrooms irradiated with UVB [7]. Vitamin D approximate content in various foods is shown in Table 1 [8].
\nFood | \nApproximate vitamin D content (μg/100 g) | \n
---|---|
Fortified | \n\n |
Milk | \n0.8–1.3 | \n
Margarine | \n8–10 | \n
Nonfortified | \n\n |
Butter | \n0.3–2 | \n
Milk | \n<1 | \n
Cheese | \n< 1 | \n
Liver | \n0.5–4 | \n
Fish | \n5–40 | \n
Major food sources of vitamin D [8].
Since most foods contain low measurements of vitamin D (Table 1), fortifying common foods is becoming a trend and common practice nowadays. In addition, nutritional supplements are a reliable solution for compensation of the vitamin deficiency [4].
\nThe Food and Nutrition Board has set an adequate intake (AI) for vitamin D due to the inability to set a more precise RDA level because of the variability in sun exposure among individuals [9]. Recommendations for vitamin D instructed an AI for vitamin D of at least 500 IU/day (12.5 μg) and more than 1000 IU/day (25 μg) for those not exposed to enough sunlight [8].
\nInternational units are used to quantify vitamin D. 1 IU is equal to 25 metric weight unit of cholecalciferol, and 1 g of cholecalciferol is equal to 40 IU [7].
\nMetabolism of vitamin D occurs through different stages that includes hydroxylation. Through these stages, vitamin ingested is transformed into its active form (Figure 2) [4].
\nSources, sites, and processing of vitamin D metabolites [
Vitamin D synthesis starts when 7-dehydrocholesterol (cholesterol precursor found on skin) is visible to sunlight and then transformed to previtamin D [9, 10]. 7-Dehydrocholesterol is an intermediate precursor for vitamin D, it is found throughout the epidermis and dermis, and thus has the most elevated limit with respect to cholecalciferol synthesis [11].
\nThe first step occurs when 7-dehydrocholesterol absorbs the UVB photons to convert them into previtamin D3. Then, photoisomerization occurs in order to covert previtamin D3 into vitamin D3 (cholecalciferol). However, it is not a problem since during delayed sun exposure previtamin D3 is converted into its inactive forms (lumisterol and tachysterol) [12].
\nLarge portion of vitamin D reaches liver from lipoproteins or vitamin D–binding protein and is then transformed by hydroxylation to yield 25-OH-D3 [4]. 25-OH-D3 is the major circulating type of vitamin D used by clinicians to evaluate vitamin D level, though it is latent and must be transformed to its active form (1α,25-dihydroxyvitamin D) in the kidneys [13].
\nWhen calcium decreases in the body, parathyroid hormone is released leading to calcitriol synthesis increase (vitamin D active form: 1α,25(OH)2D) (Figure 3). Because of the hypocalcemia (declined blood calcium), PTH is released from parathyroid gland resulting in an increase in the hydroxylation of 25(OH)D3 to calcitriol. Then, calcitriol plays its role with PTH or by itself on its target tissues leading to an increase in serum calcium levels. Kidneys, bones, and intestines are the primary target tissues [8]:
\nCalcitriol, 1,25 (OH)2 D3, synthesis and actions with parathyroid hormone (PTH) [
Increasing calcium and phosphorus absorption is the major role of calcitriol in the intestines. It works by the participation of calcitriol with cell membrane receptors to improve calcium absorption [8].
\nCalcitriol with the help of PTH increases calcium reabsorption in the distal renal tubule into the blood. Phosphorus released by the kidney is boosted and can result in lower serum phosphorus levels [8].
\nRegarding the bone, PTH plays its role with calcitriol for reabsorption increase of calcium and phosphorus from bone to reach normal blood calcium level. Osteoclasts catalyze calcium and phosphorus from bone. The net impact of this is to raise blood calcium and phosphorus levels [8].
\nVitamin D skin synthesis is negatively influenced by factors such as the following [6]:
Season: winter season decreases the quantity of ultraviolet light reaching the skin, while summer season increases it.
Skin pigmentation: dark pigments interfere with UV light entering the needed skin layer.
Clothing: covering the skin leads to inadequate sunlight skin exposure.
Calcidiol (25(OH)D) is the vitamin D metabolite that is estimated to identify a patient’s vitamin D status [14]:
Vitamin D deficiency: 25(OH)D between 21 and 29 ng/mL
Vitamin D lack: 25(OH)D < 20 ng/mL
Normal vitamin D status: 25(OH)D > 30 ng/mL
Vitamin D overproduction: 25(OH)D > 40–60 ng/mL
Vitamin D toxicity: 25(OH)D > 150 ng/mL
However, females are at 3 times higher risk of having vitamin D deficiency compared to males. There is no relationship between the age and vitamin D levels in males, but in females, those having an age between 30 and 40 are at higher risk for deficiency. But, children (10–20 years) are at highest risk for deficiency [15].
\nPractically, all consumed vitamin D is held in a nonesterified structure, which is believed to be associated with the outside of chylomicrons (lipoprotein particles). Vitamin D that is not moved in the plasma is taken up with chylomicron remainders by the liver, where it is then transferred to the same binding protein and discharged to the plasma [4].
\nVitamin D is transferred in the plasma to a great extent in association with protein, as other sterols, which is the vitamin D–binding protein (DBP) [4].
\nVitamin D storage in the liver is minimal, in contrary to other fat-soluble vitamins. Vitamin D levels do not go above 25 nmol per kg in the liver. Plasma calcidiol (25-hydroxyvitamin D) is the storage form of vitamin D, which has a half-life of 3 weeks [11]. Long-standing admission of vitamin D inside the physiological range induces storage in fat tissues and most likely in other tissues of clinical importance [16].
\nVitamin D toxicity is incredibly uncommon; however, it can occur by unplanned or purposeful ingestion of unreasonably high portions. Portions of more than 50,000 IU every day raise levels of 25-hydroxyvitamin D to more than 150 ng for each milliliter (374 nmol/L) as well as hypercalcemia and hyperphosphatemia. Portions of 10,000 IU of vitamin D3 every day for as long as 5 months do not cause toxicity [13]. Excessive exposure to sunlight represents no danger of toxicity through overproduction of endogenous cholecalciferol [8].
\nWhen calcium plasma concentrations reach 2.75–4.5 mmol/L, vitamin D toxicity causes several symptoms such as nausea, appetite loss, cramps, and diarrhea, and in more severe cases, it causes hypercalcemia. When plasma calcium levels exceed 3.75 mmol/L, hypertensive encephalopathy occurs due to the contraction of smooth muscles. Hypercalcemia and expanded vitamin D levels lead to soft tissue calcification (kidneys, heart, and lungs) [11].
\nThe most popular and worldwide deficiency currently is vitamin D deficiency [17]. It is a worry for public health and has several acute and chronic impacts. It results from wrong lifestyle starting in predominance obesity and inadequate sun exposure [18].
\nLiving with a lifestyle that is inadequate in any food group will result in a vitamin deficiency. A vitamin deficiency results in different diseases and disorders. The clinical signs and symptoms are the final stage in hypovitaminosis [4].
\nStages of vitamin deficiency are as follows:
Marginal deficiency
Stage I—depletion of vitamin stores
Stage II—cellular metabolic changes
Observable deficiency
Stage III—clinical defects
Stage IV—morphological changes
During marginal deficiency, there is only depletion of vitamin stores and its effect on cells. This depletion cannot be recognized without chemical or biochemical testing, which shows the stores’ concentrations. However, in observational deficiency, the signs and symptoms appear and morphological changes take place [4].
\nVitamin D deficiency is caused by the following [13]:
Decreased synthesis in the skin: due to creams, aging, and skin pigment, the vitamin D3 synthesis will be reduced.
Decreased bioavailability: obesity and malabsorption diminish the availability of vitamin D3.
Breastfeeding: decreased amount of vitamin D in human milk can lead to vitamin D deficiency when the child is exclusively breastfed.
25-hydroxyvitamin D diminished synthesis: vitamin D malabsorption caused by liver failure results in 25-hydroxyvitamin D diminished synthesis.
1,25 dihydroxy vitamin D diminished synthesis: decreased phosphorus excretion and decreased serum levels of 1,25-dihydroxyvitamin D are caused by chronic kidney diseases.
Vitamin D deficiency’s first stages include rickets and osteomalacia, whereas the final and long-term stages include osteoporosis in which there are chronic changes [19].
\nVitamin D deficiency in children leads to rickets. Rickets is classified by bone mineralization loss [8]. This occurs due to deficiency in both vitamin D and calcium [7]. Consequently, the bones twist due to their inability to hold the body, stand, or walk [3].
\nAs rickets occur in children, osteomalacia occurs in adults [4]. Osteomalacia is the result of the demineralization of bones [7]. In the case of osteomalacia, nonmineralized bones are much more than mineralized bones. Consequently, the patient will have muscular weakness, bone tenderness, and pain and will be at higher risk of fractures [4].
\nThe decreased ability to produce vitamin D3 in elderly due to the decrease in 7-dehydrocholesterol in the skin results in osteomalacia also. Therefore, vitamin D is essential for preventing and treating osteomalacia in elderly [7].
\nOsteoporosis is the result of inability to synthesize or get enough vitamin D from sunlight and food. This results in bone calcium loss and thus fractures [3]. It is due to multiple causes as aging, weakened vitamin D digestion, and decreased estrogen levels. It is widely seen in elderly, postmenopausal women, and those taking steroids [4].
\nVitamin D deficiency can in fact be prevented by different methods. These can include the following [13]:
Expose body to sun or ultraviolet radiation for the needed time.
Ingestion of 400–100 IU/day for kids and 800–1000 IU for grown-ups.
Control serum phosphate in case of kidney disease.
Sustaining maintenance level.
International Osteoporosis Foundation (IOF) study showed that almost all countries have 25(OH)D3 levels beneath 30 ng/ml, while South Asia and Middle East have levels beneath 10 ng/ml [19].
\nThe most widely seen medical issue in Middle East and North Africa is vitamin D deficiency. This results in diseases and disorders and most widely osteomalacia. Results showed 50–90% 25(OH)D3 deficiency, and these patients have levels below 20 or 30 nmol/ml [15].
\nResults showed higher rates of vitamin D deficiency in Lebanon especially Beirut regions as 57.86% were deficient using a cut-off of 20 ng/ml [15].
\nFemales are 3 times more prone to have hypovitaminosis D. An investigation on Lebanese grown-up population has demonstrated that hidden ladies had just about 3 times more incidence of extreme hypovitaminosis D than nonhidden subjects [15].
\nResults verified that females are at more risk to have vitamin D deficiency. Besides, hidden ladies are 3 times more at risk than nonhidden ladies [15].
\nFortification is the process of supplementing food with needed nutrients for their health benefits and in order to prevent diseases as defined by the Codex General Principles [20].
\nFortification levels differ from one nation to another according to different factors. These factors include the dimension of enrichment, the bioavailability of the fortificants, and the range of fortified consumed foods. Fortification can be achieved by adding a single nutrient (such as the addition of iodine to the salt), or by adding a blend of nutrients [20].
\nThe general medical advantages of fortification include the following [20]:
Prevention of micronutrient deficiency
Correction of a micronutrient deficiency
Achieving the health benefits of a nutrient (for example, there is some proof to recommend that a diet full in selected antioxidants may aid in preventing cancer and different disorders.)
In order to prevent or defend rickets, humans usually used one teaspoon of cod liver oil daily (1 teaspoon has 10 μg = 400 IU of vitamin D). Vitamin D food fortification started in the 1940s in the US and other nations such as Britain. In the beginning, vitamin D was supplemented to milk and then to other foods and beverages. However, in the 1950s, events of hypercalcemia appeared, and an adjustment was done for fortifying foods with vitamin D. As a result of that, few side effects of hypercalcemia had been seen in newborn children in the former German Democratic Republic, where babies were enriched with discontinuous portions of 15 mg (600,000 IU) of vitamin D as a push to defend rickets. In these newborns, serum 25(OH)D levels increased to a few hundred nmol/L [17].
\nVarious techniques for fortification of foods with vitamin D were accomplished. In a study done for the evaluation of fortifying cheddar cheese with vitamin D methods, vitamin D3 was supplemented by: addition of a water-soluble emulsion, crystalline liposoluble vitamin D, or water-soluble vitamin D multilamellar liposomes [21]. Results showed better recovery of vitamin D3 in liposomes than that in homogenized cream and water-dissolved emulsions. Similar results were shown in commercial water and fat-soluble types of vitamin D3 in delivering an evenly dispersed concentration of vitamin D3 in prepared cheddar [22].
\nVitamin D3 was fortified into a cheddar-like matrix, yogurt, or dessert in either a crystalline or an emulsified structure. The emulsified structure was more stable in cheddar over a three-month storage period at 4°C, with roughly 6% of the crystalline vitamin D3 lost under these conditions, while the two types of vitamin D3 were stable in yogurt and dessert with storage for the normal shelf life of the items [23].
\nVitamin D fortification levels determination requires the following [24]:
Survey about the quality of the diet and amount of ingested nutrient in a target population
Average sun exposure adequacy in accomplishing vitamin D adequate levels
The recent vitamin D levels in the country
When the fortification program is achieved, supervising and assessments should continue to get better data and higher effectiveness [24].
\nVitamin D food fortification is affected by factors such as availability of fortificants and suitable vehicles for the fortificant [24]:
Availability of mechanical experience in producing D2 and D3.
Having a good capacity for raising 25-hydroxyvitamin D blood concentration.
Having different formulas that suit all foods: the fat-rich items and fat-poor foods. For example, a formula of dry preserved vitamin D is found and has benefits as it contains antioxidant that defends the strength of vitamin D for extended time, yet within the appearance of minerals.
Having the proper vehicle for fortification:
Widely consumed food must be used as fortification vehicle, financially available, and consumed all through the year.
The fortification vehicle must ensure an even scattering by economical technologies.
Vitamin D bioavailability in fortified items, for example, milk, milk powder, and cheddar.
Vitamin D fortification vehicle must have negligible olfactory impact.
FDA authorizes the use of nutrients as supplements and additives after enough scientific safety reviews. The additive must be used under the law to stay in the safe side. Several studies were done to set a law for the use of vitamin D and its safety [25].
\nVitamin D is available in different structures. The two main structures are vitamins D2 and D3. Vitamin D is certified and commonly identified as safe (GRAS) to be used in food, with the following exact conditions [25].
\nFDA authorized adding vitamin D to infant formulas, calcium-fortified foods and beverages, breakfast cereals, certain cheese and cheese products, soy beverages, and milk and milk products [25] (Table 2).
\nCategory of food | \nMaximum levels in food (as served) | \n
---|---|
Breakfast cereals | \n350 IU/100 g | \n
Grain products and pasta | \n90 IU/100 g | \n
Milk | \n42 IU/100 g | \n
Milk products | \n89 IU/100 g | \n
Maxim levels of vitamin D in foods [25].
The IOM (Institute of Medicine) specified the maximum allowed daily intake as UL of a supplement that represents safety of conflicting impacts when the supplement is ingested over delayed time [25].
\nThe USA began vitamin D milk fortification in 1930s. In the USA, vitamin D food fortification is optional. They focus on food vehicle and the practical and dimensional use in order to avoid fortification above what is recommended by the FDA. The addition of vitamin D commonly in conjunction with calcium is usually to several foods including orange juice, breakfast grains, rice, and soy milk [24].
\nVitamin D widely used concentration is 100 IU per serving. The consumption of foods that have been fortified with vitamin D significantly increased 25(OH)D blood levels. The average personal intake of almost 11 μg/day (440 IU/day) from fortified foods (range 120–1000 IU/day) raised 25(OH)D levels by 7.7 ng/mL. Said relation correlates to a 0.5 ng/mL rise in 25(OH)D for every 40 IU (1 μg) ingested/day calories [24].
\nA couple of studies have researched the long impact of additional vitamin D3 on the initial vitamin D load of milk. Hollis in his article “Vitamin D and Its Metabolites in Human and Bovine Milk” demonstrated a 10-fold rise of vitamin D3 consumption from 100 to 1000 μg/d and contributed a 7·5-fold rise in vitamin D3 levels of the milk and a 2-fold rise in 25(OH)D3 [26].
\nTwo frequently used strategies to fortify eggs with vitamin D are: increasing sunlight exposure and supplementing bird diet with vitamin D. It is proved that eggs that were exposed to light have higher vitamin D3 content. Browning and Cowieson verified the effectiveness of diet enrichment with vitamin in increasing both vitamin D3 and 25(OH)D3. However, Browning, Cowieson, and Duffy verified that addition of 25(OH)D3 had positive impact on 25(OH)D3 level of the egg yolk. Thus, within a diet, 25(OH)D3 could be consumed straightforwardly by hens with no exchange to vitamin D3 within the circulation [26].
\nIt is verified that vitamin D is stable during pasteurization, manufacturing, and maturing. It is evenly distributed in the cheddar and does not influence the flavor. The positive part is that vitamin D has the same effect in supplements and in cheddar matrix. The disadvantage in fortifying cheddar with vitamin D is the loss in the wheying off step. However, it is solved by decreasing the whey load before manufacturing and the use of ultrafiltration (UF) [27]. Ganesan proved vitamin D stability over a 9-month maturity period while using typical types of vitamins. The use of UF to cheddar milk results in little yet considerable reductions in vitamin D losses in whey [28].
\nBread is a widely consumed food item; it is prepared from flour and water by baking, as well as nongrain material such as nuts, fats, raisins, and nutrients to improve the nutritional quality of the meal eaten. Vitamin D can be added during different stages (fermentation, baking, and storage). It is verified that 60 min is the reasonable time for dough fermentation, since when raising the fermentation time, oxidation of vitamin occurs [5].
\nIn the USA, milk is commonly enriched with vitamin D with an amount of 400 IU per quart. Vitamin D fortification occurs before pasteurization step, and the liquid milk shelf life is usually 1 year at room temperature and in dark [29].
\nThe stability of vitamin D throughout production and storage in dairy and milk products is verified, as well as its stability in high temperature short time handling and storage without light and acid [29].
\nVitamin D loses its stability in some conditions. It decreases in acidic media as it transforms into its inactive form isotachysterol, or by heating to a temperature above 150°C in the presence of air [27]. However, it is stable at temperatures below zero, at 4–8°C, at 25°C, and during cooking at 200°C [24].
\nIn the study of elevating vitamin D3 under two different conditions, high temperature processed decreased fat milks (increased temperature/decreased time, pasteurized at 73°C for 15 s, and ultra-heat treated, purified at 138°C for 2 s) and reduced fat yogurt (purified at a temperature of 85°C for a half hour), it is verified that the amount of vitamin D does not decrease during preparation [30]. In addition to that, it was stable during storage and has no effect on sensory qualities [23].
\nBanville found that vitamin D3 fortification in cheddar in the liposome form decreased after 3–5 months of maturing and lost its stability [21]. It is shown also that vitamin D3 has stability in nonfat foods such as in squeezed orange (storage for 30 days at 4°C) [31]. Both vitamin D3 and vitamin D2 showed their stability in fortified squeezed orange [32].
\nEven at maximal level of fortification (1200 IU), there were no flavor differences in vitamin D–fortified milk. This shows that increasing the concentration of vitamin D is better to improve the nutritional quality and increase vitamin D amount ingested and do not influence the liquid milk flavors [29].
\nOdors were affected by vitamin D fortification, as they give rancid oil and painty odor. However, it is shown that the aroma depth is way more in water source than that in oil source. In oil sources, the aroma depth is lesser due to the oil matrices found that defend oxidation. After vitamin D oxidation occurs, aldehydes are found in the product [29].
\nThe Association of Official Analytical Chemists (AOAC) International, which set up authority and “legally defensible analytic” strategies in the United States, has approved the accompanying chemical techniques for the examination of vitamin D in foods [23]:
\nMethod 980.26: vitamin D in multivitamin preparations
\nMethod 981.17: vitamin D in fortified milk and milk powder
\nMethod 982.29: vitamin D in mixed feeds, premixes, and pet foods
\nMethod 992.26: vitamin D3 in ready-to-feed milk-based infant formula
\nMethod 995.05: vitamin D in infant formulas and enteral products (for tube feeding)
\nMethod 2002.05: cholecalciferol (vitamin D3) in selected foods (fortified milk, infant formula, gruel, margarine, and cooking and fish oil)
\nThe AOAC strategies recorded above are alike on a basic level. Every strategy includes four key advances [23]:
A digestion step to break down the food matrix (alkaline saponification)
An extraction step for the separation of vitamin D from the food matrix
A clean-up step, to isolate vitamin D from other food components
Quantitative detection by HPLC with UV
However, these strategies are time-, work-, and expert-consuming. Besides that, they are allowed only for restricted items (generally dairy), and not suitable for nonfat items in certain countries. The AOAC techniques target vitamin D3, and not vitamin D2, that might be available either normally or as a fortificant [23].
\nInstrumental techniques for the analysis of vitamin D in foods incorporate [23]:
partition by high-pressure liquid chromatography (HPLC),
detection by ultraviolet absorption (UV), and
diode array detection (DAD) or mass spectrometry.
The accompanying approach was created, approved, and used to survey vitamin D3 levels in Danish pork and dairy items [33, 34]:
Homogenization and addition of vitamin D2 internal standard
Digestion by alkali saponification for 45 min in a boiling water bath
Extraction with petroleum ether: diethyl ether
Clean-up with silica solid-phase extraction columns
Purification with semipreparative HPLC (amino + silica columns, normal phase)
Detection by reverse-phase HPLC with DAD
It is verified that the oral use of 25(OH)D3 is efficient in rising plasma 25(OH)D levels [26]. The common level of vitamin intake range is between 10 and 20 μg/d. Cashman in his study gave adults (mean age of 57 years) 20 μg vitamin D3 or 20 μg 25(OH)D3 for those having with serum 25(OH)D of 28·9 nmol/l in winter. The results showed after 2.5 months treatment an increase in both vitamin D3 and 25(OH)D3. Jetter in his study provided fit postmenopausal ladies with 20 μg 25(OH)D3 or 20 μg vitamin D3 for about 4 months over the winter. The results showed better effectiveness of 25(OH)D3 than that of dietary vitamin D3 [26].
\nResults showed better effectiveness for 25(OH)D3 in absorption and increasing the plasma levels. In addition to that, 25(OH)D3 is better for human health as Bischoff Ferrari et al. proved a decline in systolic blood pressure and enhancements in a few markers of immunity in healthy postmenopausal ladies. Also, 25(OH)D3 supplementation corrected the excess bone turnover, improved plasma lipid level rise in HDL cholesterol, and diminished LDL-cholesterol in osteopenic and dyslipidemic postmenopausal ladies [26].
\nAfter referring to various studies considering fortifying foods and dairy products with vitamin D, it is proven that dairy product vitamin D fortification is an effective strategy to diminish the prevalence and incidence of vitamin D deficiency among populations. This is because this method is cost-effective regarding its positive effect on public health and its impacts with minimal sensorial changes including flavor and order. Dairy products have been shown to be a suitable food type to be fortified with vitamin D. Milk and many cheese products, and yogurt are fortified with vitamin D and have shown to be stable and an effective source of vitamin D, and this is why we can consider other types of dairy products to be fortified with vitamin D like Labneh, in which further research will be done in order to test for stability of vitamin D and the most appropriate form to be used in it. According to the appropriate form of vitamin D used in dairy products, liposomes of vitamin D are effective for cheddar cheese fortification. This method proves the effectiveness and liposomes of food fortification that has been followed for years, a strategy that tremendously leads to decreasing the burden of nutrition deficiency among populations especially in developing countries. In fact, public awareness stays a must in promoting education about vitamin D deficiency, its symptoms, risk factors, and causes.
\nThe authors declare no conflict of interest.
While public health crises, such as the COVID-19 pandemic, have received tremendous attention and resources, one public health crisis has seemingly been forgotten for decades: The opioid epidemic. With nearly half a million Americans dead from opioid use in the past few decades and no foreseeable stop to the increasing number of opioid overdose deaths, the United States is in need of immediate solutions to the opioid crisis. One emerging solution to combat the opioid crisis is facilities known as safe injection sites. Safe injection sites allow people who inject drugs (PWID) to safely inject addictive substances in the presence of healthcare professionals. While safe injection sites have been successful in countries across the world for decades as a solution to the opioid crisis, they have recently been a topic of debate in the United States. Especially in cities, such as Philadelphia, where the opioid crisis is one of the worst in the nation, safe injection sites are an extremely promising solution.
Before safe injection sites are able to be discussed in detail, this paper will first provide a background to the opioid epidemic, highlighting the role of pharmaceutical companies, physicians, the Drug Enforcement Agency (DEA), and the Food and Drug Administration (FDA) in exacerbating the opioid crisis in the United States. The three stages of the rise in opioid deaths will also be discussed in this section, showing the transition from predominately prescription opioid overdose deaths to heroin overdose deaths, and then the more recent transition to synthetic opioid overdose deaths. In addition, the impact of the COVID-19 pandemic on the opioid epidemic will be described, especially its role in exacerbating the opioid crisis in the United States.
With an understanding of the background of the opioid epidemic, this paper will then provide an analysis of a case study regarding the opioid crisis in the Kensington region of Philadelphia, which is one of the most impacted areas by the opioid epidemic in the country. Furthermore, this paper will then provide a detailed breakdown of the history of safe injection sites, along with their respective risks and benefits. The implications of safe injection sites for the United States will especially be emphasized in this section, along with the recent legal battle to bring safe injection sites to Philadelphia and other areas of the country. An ethical analysis of safe injection sites will then be provided from a Catholic social teaching perspective using the principles of the respect for human dignity, solidarity, the common good, and the stewardship of resources, and the relationship of safe injection sites to the harm reduction theory will also be discussed. The ethical analysis will provide an argument as to why safe injection sites should be implemented in the United States. Lastly, we will make seven recommendations for the successful and effective implementation of safe injection sites in the United States, highlighting legal, medical, educational, social, and financial aspects.
Since the 1990s, the opioid epidemic has been a devastating problem in the United States. According to the Centers for Disease Control and Prevention (CDC), between 1999 and 2019, nearly 500,000 people in the United States died from a drug overdose involving opioids, which accounts for nearly two-thirds of the total drug overdose deaths [1]. In 2019 alone, nearly 70% of the 70,630 drug overdose deaths involved opioids, and the total number of deaths from drug overdoses was four times higher in 2019 as compared to 1999 [1]. While the opioid epidemic has ravaged the United States for decades, it has not always been at the forefront of public health concerns. In 2015, Anne Case and Angus Deaton, two extremely well-known economists with the latter being a Nobel Prize winner, brought the opioid epidemic to the spotlight. While investigating morbidity and mortality rates for men and women from the CDC, Case and Deaton discovered a puzzling trend: There was a striking increase in the morbidity and mortality of middle-aged white non-Hispanic individuals between 1999 and 2013 [2]. According to Case and Deaton, between 1978 and 1998, the mortality rate for middle-aged (45–54 years old) white non-Hispanics in the United States fell by 2% per year on average [2]. However, beginning in 1999, the mortality rate for middle-aged white non-Hispanics in the United States rose by an average of half a percent a year until 2013 [2]. At the same time mortality rates were increasing for non-Hispanic whites, morbidity rates experienced a direct increase as well. In a self-reported assessment of health status from 1997 to 1999, there was a 6.7% decrease in middle-aged non-Hispanic whites from the United States reporting excellent or very good health and a related 4.3% increase in middle-aged US non-Hispanic whites reporting an increase in fair or poor health. At the same time, mortality and morbidity were increasing in the United States between 1999 and 2013 for middle-aged US non-Hispanic Whites, self-reported declines in health, mental health, increases in chronic pain and inability to work, ability to conduct daily activities of living, and clinically measured deteriorations in liver function [2]. All of these factors interestingly coincide with the increased availability of prescription opioids for pain during the 1990s [2].
The prevalence of different types of opioids has fluctuated throughout the epidemic in three distinct waves, with the first wave of the opioid epidemic involving the increased prescription of opioids. Prescription opioids, such as OxyContin and Vicodin, are frequently used to treat moderate-to-severe pain after surgery and chronic pain [3]. While the use of prescription opioids was originally intended for chronic pain from diseases, such as cancer, or for short-term use for recovering after surgery, in the 1990s medical professionals began expanding the use of opioids [4]. Physicians began to increase the long-term use of opioids in treating chronic nonmalignant medical conditions, which include conditions, such as sciatica and low-back pain [4]. Physicians were especially influenced and encouraged to increase the usage of prescription opioids, such as OxyContin, through aggressive marketing tactics from drug companies [4]. For the physicians, the message to “be proactive with pain and treat it aggressively,” seemed to make perfect sense, and promoted the use of prescription opioids, such as OxyContin [4]. In 1995, OxyContin, a prescription opioid-containing the highly addictive compound oxycodone produced by Purdue Pharmaceutical, was approved by the United States Government. OxyContin was initially approved as an extended-release reformulation of oxycodone that was intended to reduce abuse and addiction [5]. Since opiates at the time were being used recreationally and it was widely believed that individuals with chronic pain needed more help, OxyContin was readily approved [6]. However, Purdue Pharmaceutical clearly lied and deceived the public by claiming that OxyContin’s delayed absorption ability reduced the “abuse liability of the drug” [7].
Even though OxyContin was advertised to be less abusive than other opioids, Purdue Pharmaceutical had actually conducted a study in 1995 showing that 68% of oxycodone could be extracted from an OxyContin tablet when crushed [6]. Evidently, Purdue Pharmaceutical knew how highly addictive OxyContin was, but continued to lie about their product to increase sales. With this completely false claim of reducing potential abuse of OxyContin and the unwavering message to alleviate pain whenever possible, Purdue Pharmaceutical was able to successfully market their drug to physicians, which resulted in sales increasing from $48 million in 1996 to approximately $1.1 billion in 2000 [8]. For the next 20 years after 1995, prescription opioids, such as OxyContin, experienced a 10-fold increase in medical use. Interestingly, family medicine physicians with no expertise in pain management prescribed more opioids than any other type of physician, even pain specialists. In 2012, 18% of all opioid prescriptions were written by family medicine physicians, 15% were written by internists, and only a mere 5% were written by pain specialists [4].
Despite the rapid increase in the use of prescription opioids, such as OxyContin, in the United States beginning in the late 1990s, OxyContin was not even more effective than alternative drugs. For example, a randomized double-blind study showed that giving OxyContin every 12 hours produced comparable efficacy and safety results when treating chronic back pain as giving immediate-release oxycodone four times daily [9]. In addition, when treating patients with moderate to severe cancer-related pain, a randomized double-blind study showed that OxyContin given every 12 hours was as effective as immediate-release oxycodone given four times daily [10]. Even during the FDA’s review of OxyContin in 1995, the FDA’s medical review officer concluded that OxyContin had no significant advantages over immediate-release oxycodone [6]. Along with not producing a significant advantage over other alternatives, there have been no studies affirming the long-term effectiveness of OxyContin [3]. Moreover, in 2006, a Danish study with a national random sample of over 10,066 individuals that compared opioid users to non-opioid users revealed that opioid usage was significantly associated with reports of moderate/severe or very severe pain, poor self-rated health, unemployment, increased use of the health care system, and a lower quality of life [11]. With OxyContin seeming to have more negative effects on patients than positives, it is evident that its producer, Purdue Pharmaceutical, is at fault. As Oxycontin became one of the most prescribed opioids in America, it had also become one of the most abused drugs in America by 2004, resulting in an increasing number of opioid overdose deaths [12]. From 1999 to 2017, the number of opioid overdose deaths involving prescription opioids increased from 3,442 to 17,029 deaths [13].
While Purdue Pharmaceutical did nothing to inform the public about these harms, physicians are not infallible for their propagation of the opioid epidemic. Even after the addictive nature of opioids has become apparent in the past two decades, prescription opioids are still heavily utilized. In 2017 alone, over 191 million opioid prescriptions were dispensed to American patients [3]. In addition, the long-term use of prescription opioids by an individual is connected to the prescribing patterns of the original physician they encountered [14]. For example, researchers discovered that doctors they marked as “high-intensity” prescribers sent one out of four patients home with opioids, while “low-intensity” prescribers gave opioids to one out of 14 patients, and patients that saw a “high-intensity” prescriber were over 30% more likely to become long-term users of prescription opioids [14]. While physicians played a role in starting the opioid epidemic, they can continue to exacerbate it if prescription opioids continue to be prescribed at high frequencies.
Along with physicians and large pharmaceutical companies, such as Purdue Pharmaceutical, the Drug Enforcement Administration (DEA), further worsened the opioid epidemic. For example, in 2019, the Justice Department’s inspector general criticized the DEA’s decision to authorize manufacturers to tremendously increase the production of prescription opioid painkillers between 2003 and 2013 while opioid-related deaths in the United States surged [15]. The DEA directly oversees access to opioids, regulates opioid production quotas, and investigates illegal diversions of opioids [15]. However, the DEA failed to adequately respond to the opioid crisis as it increased the production quotas for oxycodone production by nearly 400% between 2002 and 2013, even though there was significant evidence that opioids were being abused and overprescribed [15]. The DEA also further did not capture proper data on opioid abuse and other drug trends between 2002 and 2013, thereby further handicapping their ability to properly mitigate the opioid crisis [15].
Along with the DEA, the Food and Drug Administration (FDA) further failed to deal with the opioid epidemic properly. For example, the FDA failed to use its policing powers by providing no oversight or measure of effectiveness for a safety training program that aimed to reduce the improper prescription of opioids [16]. In 2007, Congress explicitly gave the FDA the power to require the manufacturers of opioids to give training to physicians so that they could properly prescribe opioids, and the FDA was allowed to monitor the performance of these drug companies [16]. With this power, in 2011, the FDA asked producers of OxyContin and other addictive long-term opioids to pay for safety training for nearly 320,000 physicians prescribing their drugs, and also asked these entities to track the effectiveness of this training and measure other factors, such as reducing addiction, overdoses, and deaths [16].
Even though the safety program sounded good in theory, in practice it was doomed from the beginning. For example, the FDA never determined if the program worked as the opioid manufacturers were not properly collecting the right type of data, and the FDA made the critical mistake of leaving the monitoring of these safety programs in the hands of the drug manufacturers. In 2010, the FDA advisory committee of experts was aware of these potential flaws in the program’s design and voted 25–10 against its implementation; however, the FDA still implemented the flawed program [16]. In addition, in 2013, a report by the inspector general of the Department of Health and Human Services showed that only 14% of the safety programs that the FDA reviewed actually met their goals, and that the FDA had no enforcement actions against companies that did not provide enough information about their safety program for it to be reviewed [16]. Hopkins researchers discovered that even though the FDA was aware of these problems after performing their own review process, they still did nothing to change it, and ultimately failed to regulate the opioid manufacturers [16]. This improper decision-making seemed to be driven by a conflict of interest between opioid manufacturers and the FDA staff responsible for opioid oversight [17]. Shockingly, the two FDA reviewers that originally approved Purdue Pharmaceutical’s oxycodone application joined Purdue after leaving the FDA [17]. With a conflict of interest and the lack of action, the FDA made no progress in limiting the devasting impacts opioids were having in the United States, and ultimately played a critical role in exacerbating the opioid crisis.
While prescription opioids started the opioid epidemic in the United States, the second wave of the opioid crisis, starting in 2010, saw a rapid increase in the number of opioid overdose deaths using heroin. According to the CDC, between 2010 and 2018, opioid overdose deaths involving heroin increased by a factor of 5 from 3,036 deaths in 2010 to 14,996 deaths in 2018 [18]. In 2018, it was estimated that over 808,000 individuals had used heroin in the United States [19]. While heroin use only started to spike around 2010, it has accounted for nearly a third of all opioid overdose deaths contributing to the death of over 115,000 Americans between 1999 and 2018 [18]. Furthermore, heroin is often combined with other drugs and alcohol, leading to a greater chance of overdose. In 2013, it was reported that over 96% of heroin users use another drug, while 61% report using at least three different drugs [20]. Since heroin is typically injected using needles, heroin users are also at risk of contracting HIV, Hepatitis B, and Hepatitis C. In 2017, the CDC reported that almost 9% of the 38,738 diagnoses of HIV in the United States resulted from the injection of drugs, such as heroin [21].
Despite the devastating impact that heroin and prescription opioids have had on the United States during the opioid epidemic, the third wave of the opioid epidemic, starting in 2013, has been characterized by the development of deadly synthetic opioids. The use of synthetic opioids, such as fentanyl and Tramadol, is currently the leading cause of opioid deaths. For example, in 2018, over 31,000 people died from overdoses involving synthetic opioids excluding methadone, which was a 10% increase from 2017 [22]. From 2010 to 2013, the national rate of synthetic opioid overdose deaths was approximately 1 per 100,000 individuals, while this rate tripled from 2013 to 2015 to nearly 3.1 synthetic opioid overdose deaths per 100,000 individuals [23]. Fentanyl is particularly problematic as it is 50–100 times more potent than morphine, and is often mixed with heroin and cocaine without the knowledge of the user, as it can increase the euphoric effects [22].
With the increased usage of synthetic opioids in recent years, the opioid epidemic began to emerge as a public health crisis. On October 26, 2017, President Trump officially declared the opioid epidemic a “public health emergency” [24]. With this declaration, President Trump instructed the Health and Human Services (HHS) secretary, Eric D. Hargan to declare the opioid epidemic a public health emergency [24]. With Hargan’s declaration, HHS was allowed to allocate resources and personnel to face the opioid epidemic [25]. In particular, on March 20, 2018, a National Health Emergency Dislocated Worker Demonstration Grant became available to individuals who experienced economic and workforce-related impacts caused by the opioid crisis [26]. Through providing this grant, training opportunities for skilled professions were encouraged to help those struggling with addiction to have a path back to the workforce.
While progress in mitigating the opioid epidemic has occurred in recent years, the development of COVID-19 has exacerbated the crisis. Before COVID-19, between 2017 and 2018, opioid-involved deaths decreased by 2%, prescription-opioid involved death rates decreased by 13.5%, and heroin involved deaths decreased by 4% [3]. With drug overdose mortality declining for the first time in over two decades, there was room for optimism in 2018 that the opioid epidemic was finally starting to become under control [27]. However, between 2018 and 2019, drug overdose deaths climbed once again up to 70,000 deaths [27]. This increasing trend in drug overdose deaths starting before the COVID-19 pandemic, has only continued to increase as a result of the pandemic. For example, provisional drug overdose deaths experienced an increase of 2,146 deaths from 75,696 deaths in the 12-months ending in March 2020 to 77,842 deaths in the 12-months ending in April 2020, and drug overdose deaths experienced a 3,388 death increase from the 12-months ending in April 2020 to 81,230 deaths in the 12-months ending in May 2020 [28]. What makes these numbers so alarming is that the increase of 2,146 provisional drug overdose deaths and 3,388 provisional drug overdose deaths mark the largest monthly increases since provisional 12-month estimates began to be calculated in January 2015 [28]. Even more alarming is the fact that in a 12-month period ending in September 2020, more than 87,000 Americans died from drug overdoses, which was the highest number ever recorded since the start of the opioid epidemic in the 1990s [29]. Moreover, the opioid crisis has even caused more devastation than COVID-19 in cities, such as San Francisco, where in 2020, the number of drug overdose deaths skyrocketed to 713 deaths as compared to the 257 individuals who died of COVID-19 that year [30].
With record-breaking monthly and annual surges in drug overdose deaths recorded at the start of COVID-19’s declaration as a national emergency, it is clear that the pandemic has been responsible for increasing the number of drug overdose deaths. While we know this is happening, why is the pandemic increasing drug overdose deaths? First of all, while social distancing has been critical in mitigating the COVID-19 pandemic, it has also unfortunately been extremely problematic for those recovering from drugs or for individuals that use drugs. For example, access to essential treatments and community groups has been disrupted, as individuals have been instructed to stay away from others during the pandemic [27]. While recommendations to avoid individuals have been generally seen as positive, an unintended consequence of these recommendations is that they conflict with the harm reduction theory’s principle of never using alone [27]. Furthermore, the pandemic is tremendously increasing the reasons people have to use drugs, such as opioids, as it has increased unemployment, feelings of loneliness and hopelessness, poverty, and a general desire to escape [27]. As people lose their jobs and experience economic and social turmoil, drugs like opioids are readily being seen as a remedy for these troublesome issues.
With the devastation that the pandemic has caused to the lives of so many individuals, it is not a surprise that heroin and synthetic opioids usage and deaths have seen tremendous rises. In a study of over 150,000 urine samples ordered by health professionals 4 months before the national emergency declaration (November 14, 2019, to March 12, 2020) and after (March 13, 2020, to July 10, 2020), fentanyl prevalence increased from 3.80% to 7.32% and heroin prevalence increased from 1.29% to 2.09% [31]. In addition, in a study of over 500,000 definite drug test results from Millennium Health in the periods before and after the national emergency for COVID-19 was declared, the national findings revealed a 31.96% increase in non-prescribed fentanyl, 19.69% for methamphetamine, 10.06% increase in cocaine, and a 12.53% increase for heroin [32]. Along with the rise in heroin and synthetic drug usage, drug overdose deaths from both of these types of opioids have increased as well. For example, between the 12-months ending in June 2019 and the 12-months ending in May 2020, the 12-month count of synthetic opioid deaths increased by over 38.4% [28]. The increase in drug overdose deaths from heroin is co-linked with drug overdose deaths, as overdose deaths from cocaine typically combined with heroin increased by 26.5% [28]. While COVID-19 has resulted in the death of over 530,000 individuals in the United States as of March 2021, the COVID-19 pandemic has only accelerated the usage and drug overdose deaths from opioids, and has pushed the opioid epidemic out of the concern of the public eye [33].
Philadelphia is home to the worst opioid crisis in the United States. Of the 10 most populous counties in the United States, Philadelphia has the highest overdose rate [34]. In addition, according to the Philadelphia Department of Public Health, in 2019, over 1,150 people died from drug overdoses in Philadelphia with 80% of these overdose deaths involving opioids [35]. The COVID-19 pandemic has further caused an 11% increase in the number of drug overdose deaths in Philadelphia in the first three quarters of 2020 compared to the same period in 2019 [36]. The pandemic has been especially devastating for Black and Hispanic Philadelphians, as drug overdose deaths in the first three quarters of 2020 increased by over 40.3% for Black Philadelphians and increased by 5.9% for Hispanic Philadelphians while decreasing by 7.3% for white residents [36]. These discrepancies have been accounted for by explanations of systemic racism experienced by Black and Hispanic individuals that result in less access to treatment, education, and economic resources [36].
Even though the number of deaths is troubling, the number of Philadelphians addicted to opioids is even more problematic. In 2017, the Philadelphia Department of Public Health estimated that over 75,000 of its residents are addicted to heroin and other opioids [35]. At the center of the opioid crisis in Philadelphia is one main neighborhood: Kensington. The Kensington District is home to one of the largest open-air drug markets in the United States, with buyers and sellers of heroin and other opioids roaming the streets at all hours of the day [37]. Of the 1,217 people that fatally overdosed from drugs in Philadelphia in 2017, 236 individuals fatally overdosed in Kensington alone [35]. With high levels of opioid use and fatal drug overdoses, individuals in Kensington live in a perpetual state of suffering.
One resident of Kensington, Crystal, a 34-year-old mother of three children, is a devout heroin addict. Crystal is originally from the Kensington area and had several other of her relatives that were addicted to heroin [34]. After Crystal’s husband lost his job, Crystal began to utilize heroin as a coping mechanism for this loss. As Crystal and her husband divorced, she continued to abuse heroin, and eventually found herself living on the streets of Kensington without her children. Through further suffering a broken ankle, Crystal continued to use heroin as a means to escape. Crystal would constantly need to be revived by Narcan, as she was heavily addicted to heroin. The heroin in Kensington, known as “Philly dope,” is especially more dangerous as it is often laced with the dangerous synthetic opioid, fentanyl [34]. The heroin is also extremely cheap in Kensington at only $5 a bag making it accessible to numerous individuals. With these factors, Crystal remained in a state of a constant dependency on heroin. When she was without it, she would experience tremendous episodes of withdrawal. Crystal described this lifestyle as “playing Russian roulette with your life,” but sadly like many other Kensington residents, she was too addicted to leave this lifestyle behind [34].
Although heroin users from Kensington like Crystal can grow up in Kensington, many users are drawn to the area for its reputation as “the Walmart of heroin” [34]. One middle-aged woman named Jax migrated to Kensington to start shooting up heroin. Jax was originally a college student that started using opioids in college but eventually became a prostitute after shooting up heroin in Kensington. Jax tried to remain sober by checking herself into rehab centers but could never escape the addiction. Despite having the initial support of her boyfriend, Jax’s boyfriend eventually left, leaving Jax alone to continue her heroin use. Like many women in Kensington, Jax turned to prostitution to pay for bags of heroin. Prostitutes in Kensington have been raped, tied up, and abused but are often afraid to tell police about their abuse due to their previous drug or prostitution charges. After becoming pregnant in 2009, Jax used heroin for the whole nine months, and her resulting son currently does not live with her. In 2018, Jax spent 24 days in jail, but after being released, she overdosed nine times in two weeks. Despite being saved from death on numerous occasions, Jax simply wishes that people would “just let me die” [34].
As shown through the examples of Crystal and Jax, individuals from all different backgrounds can be drawn into devastating opioid addictions. Crystal inevitably became a product of her own environment, while Jax was attracted to Kensington for its powerful opioids [34]. Although each woman experienced unique life challenges, their current lives are plagued by a constant presence of overdosing and dependence on heroin. While these women could potentially benefit from rehab centers, it is evident through cases like Jax that these rehab centers are simply not enough. Even when Philadelphia mayor Jim Kenney attempted to clean up the streets of Kensington in 2017, displaced residents from his projects continued to refuse the city’s offer of treatment [34]. While rehab centers are unlikely to benefit Crystal and Jax, safe injection sites could potentially allow these individuals to slowly escape their heroin addiction, and at least mitigate the harm of abusing heroin.
While safe injection sites have been a recently new topic of discussion in the United States, they have benefited other countries for decades. Canada decided to become the first North American country to implement safe injection sites in 2003. Leading up to their decision, Canada had been experiencing health-related and social harms with injection drug use, especially in Vancouver [38]. In the mid-late 1990s, Vancouver’s health authorities declared a public emergency after trends showed over 300 annual fatal overdoses occurring in the province of British Columbia, along with an annual new HIV infection rate of approximately 19% among local people who inject drugs [38]. As a result, the first legally sanctioned safe injection site opened in Vancouver in 2003 [38]. The Portland Hotel Society (PHS), a non-government organization, was responsible for the creation of the first sanctioned site, which initially began by members quietly building the safe injection site in a seemingly boarded up vacant building [38]. The regional health authority decided to work with PHS to open the site after its development in the form of a scientific pilot known as Insite, and the site received a federal exemption under Section 56 of the Controlled Drugs and Substances Act by the federal Health Ministry [38].
In the years since the creation of Insite, the results have been extremely promising. Since 2003, there have been over 3.6 million visits to inject drugs under the supervision of nurses, with 6,440 overdose interventions, and zero fatalities [39]. Along with preventing any overdose deaths, since 2003, there have been approximately 48,798 clinical treatment visits from users of illicit drugs. Furthermore, in the most recent data from 2019, Insite had 170,731 visits by 5,111 individuals, with 1,314 overdose interventions, and 3,158 clinical treatment interventions [39]. An average of 312 injections occurred at Insite per day in 2019, with 60% of these injections involving only opioids, 15% of injections involving stimulants only, and approximately 24% of injections involving a mix of opioids and stimulants [39]. Moreover, after the opening of Insite, the overdose mortality rate of all persons living within 500 m of the facility (70% of safe injection site users) decreased from 253 to 165 per 100,000 person-years, and one overdose death has been prevented for every 1137 users [40]. However, there was no change in overdose mortality elsewhere around the city of Vancouver, indicating the importance of Insite in inducing these changes. After the opening of Insite, there were also 67% fewer ambulance calls for treating overdoses, along with a decrease in HIV infections with an estimated 6–57 HIV infections being prevented per year in Vancouver [40].
Along with the tremendous benefits provided by Insite, the model has proved to be cost-effective. Insite’s operating costs are approximately $3 million per year, but the value of the benefits of Insite is much greater [41]. Without Insite, it is estimated that yearly HIV infections in Vancouver would by 83.5 infections increase from 179.3 to 262.8 infections [41]. Using the value of 83.5 preventable HIV infections, Insite has been estimated to save approximately $17.6 million in lifetime HIV-related medical costs [41]. In addition, based on more conservative estimates, Insite has been estimated to prevent around three deaths per year and approximately 35 new cases of HIV [42]. Using these values, Insite has been estimated to have a societal benefit in excess of $6 million after yearly operating costs are factored in, thereby producing an average benefit-cost ratio of 5.21:1 [42]. Moreover, another study projected that over 54 cases of hepatitis C infections would be prevented over ten years with the presence of Insite [43]. The amount of cost averted per case was estimated to be $444,500 for each hepatitis C virus infection [43]. Through these estimates, it is clear that Insite is an effective use of public health resources when analyzing the measurable benefits of HIV infection and drug overdose deaths.
With the continued success of safe injection sites in Vancouver and around the world, it is evident that safe injection sites provide clear benefits to their communities. A summarized list of the benefits of safe injection sites is as follows:
Successfully managing on-site overdoses and reducing drug-related overdose death rates
Saving costs due to reducing disease, overdose deaths, and the need for emergency medical services
Reducing the risk behavior associated with HIV and other blood illnesses, such as Hepatitis C
Increasing the entry into substance use disorder treatment
Reducing the amount and frequency individuals use drugs
Increasing the delivery of medical and social services [44].
Based on the success of Insite and other safe injection sites facilities, the number of safe injection site facilities has continued to grow. As of 2021, there are approximately 120 safe injection sites operating in ten different countries throughout the world: Australia, Canada, Denmark, France, Germany, Luxembourg, the Netherlands, Norway, Spain, and Switzerland [44]. Despite the opioid epidemic ravishing the United States, there are currently no safe injection sites in the country. However, in the past few years, several cities in the United States have been trying to change that. With the worst opioid crisis in the nation, in January 2018, the city of Philadelphia began to look toward implementing a safe injection site in the form of Comprehensive User Engagement Sites (CUES) [45]. CUES was developed with Insite as a model and adopted many of its services, such as monitoring user injection of drugs for on-site overdose care, recovery/detoxification services, referrals to treatment, and other health services, such as wound care, immunizations, and pregnancy tests [46]. CUES was also structurally similar to Insite by providing a reception area for PWID and giving each PWID a card with an anonymous identification number [46]. The purpose of the card is not to collect personal information, but rather to provide PWID the address and phone number of the facility, phone number of counseling and rehabilitation programs, and also contacts to emergency services in case of an overdose [46]. At the reception center, PWID are also asked where they heard about the site from, their age and ethnicity, along with their interest in services, such as rehabilitation, psychiatric services, wound care, and clean needle exchanges [46]. After the reception, PWID can safely inject at separate benches in a large room under the supervision of healthcare professionals, and can then briefly relax in a separate lounge area for 30 minutes. During the lounge period, educational material, counseling, and rehabilitation services are offered to PWID [46]. Unlike Insite, CUES offers additional services, such as fentanyl screenings, Hepatitis-C/HIV screenings, a needle exchange program, Narcan distribution and education, early education, and counseling for rehabilitation and detoxification done by individuals in recovery who have actually experienced drug addiction [46].
The services provided by CUES also have extremely promising impacts on population health. For example, in December 2017, SCF-averted HIV infections were estimated to range from 1 to 18 annually with the low range assuming a receptive needle sharing of 2% with the upper range assuming a receptive needle sharing of 28.3% [47]. In addition, SCF-averted hepatitis C virus (HCV) infections were estimated to range from 15 to 213 annually assuming the same receptive needle sharing ranges as used in the HIV estimates [47]. While the low ranges are possible for both averted HIV and HCV infections, the Philadelphia Department of Health estimates that the actual rate of needle sharing is closer to 28.3%, thereby suggesting that true values for averted infections should be closer to the upper limits [47]. Along with HIV and HCV infections, the estimated number of annual overdose deaths averted within 500 meters of a SCF would be between 27 and 48 deaths annually, while the number of averted overdose deaths from opening a SCF would be between 24 and 76 deaths annually [47].
Along with the health impacts, the estimated financial impacts of SCFs are quite striking. For example, the estimated total value of overdose deaths averted in Philadelphia would be between $12,462,213 and $74,773,276 annually [47]. In addition, the estimated annual savings due to SCF skin and soft tissue infection (SSTI) reductions would be between $1,512,356 and $1,868,205 annually [47]. Furthermore, estimates predict that SCF will result in savings due to a reduction in emergency room visits, hospital stays, and ambulance calls. For example, the estimated annual savings due to SCF reducing ambulance calls for an overdose is $123,776 [47]. The estimated annual savings from keeping PWID out of the emergency room is $280,683, while the estimated annual savings on hospitals for PWID who overdose would be $247,941 [47]. With these estimates, SCFs are expected to produce tremendous benefits to the health and financials of individuals in the city of Philadelphia.
With the promising impacts of safe injection sites in Philadelphia, numerous individuals in Philadelphia saw developments, such as CUES as an opportunity to successfully combat the opioid epidemic. In 2018, the Mayor of Philadelphia, Jim Kenney, and Philadelphia District Attorney Larry Krasner, both strongly supported the implementation of CUES. Instead of combating drug addiction through the criminalization of drugs by claiming a “War on Drugs,” both Kenney and Krasner wanted to approach drug addiction from more of a harm reduction standpoint [48]. Through the opioid epidemic driving violence in Philadelphia and stressing the EMS system, both Kenney and Krasner realized that immediate action was needed that focused on saving lives “in a way that research has shown to be successful.” [48]. For Kenney and Krasner, CUES provides not only a place where PWID can be safely injected under supervision, but also provides a direct link to treatment, resources for housing and meals, and the ability to save lives [48]. Krasner also expressed that he would not prosecute anyone involved in bringing safe injection sites to Philadelphia [48]. Moreover, safe injection sites, such as CUES, have the support of Philadelphia’s Health sector. In 2018, Dr. Thomas Farley, Philadelphia’s Health Commissioner and co-chair of the city’s opioid task force, also expressed his support for safe injection sites [49]. Farley described how there are “many people who are hesitant to go into treatment, despite their addiction, and we do not want them to die” [49]. Instead of letting individuals die, Farley continued to reiterate the sentiment that safe injection sites save lives and connect individuals to treatment [49]. Based on the support of numerous public officials, as of early 2018, the message for safe injection sites was clear: CUES have the greenlight to be implemented. Although, instead of paying or operating any of the safe injection sites, the city of Philadelphia would simply be a facilitator and connector with the organizations that provided addiction services [49].
With the city of Philadelphia not directly funding safe injection sites, other organizations became responsible for the implementation of safe injection sites. Within a year, a privately funded, 501 tax-exempt, Philadelphia nonprofit corporation named Safehouse, attempted to address the opioid epidemic crisis by its plan to open the United States’ first safe injection site in Philadelphia [50]. However, Safehouse’s plan was met with immediate legal resistance. In February 2019, Bill McSwain, the U.S. Attorney for the Eastern District of Pennsylvania filed a civil lawsuit that asked a federal court to declare supervised consumption sites, otherwise known as safe injections sites, illegal under 21 U.S. Code 856, which is a section of the Controlled Substances Act known as the “Crack House” Statute [50]. The Federal Comprehensive Drug Abuse Prevention and Control Act of 1970, known as the Controlled Substances Act, had the main goal of improving the manufacturing, importation, exportation, distribution, and dispensing of controlled substances [51]. To create a “closed system” for controlled substances, the Controlled Substances Act further mandated that manufacturers, distributors, and dispensers of controlled substances must register with the Drug Enforcement Administration (DEA) [51]. In addition, the Controlled Substances Act categorized controlled substances into five schedules based on their abuse potential to further aim to mitigate the potential harms of these substances [51].
In terms of safe injection sites, the Controlled Substances Act, has tremendous legal implications. For example, Section 856(a) of the Controlled Substances Act, otherwise known as the “Crack House Statute,” contains a potential barrier to establishing safe injection sites. Subsection (a) regarding the unlawful acts of Section 856 of the Controlled Substances Act is as follows:
Except as authorized by this subchapter, it shall be unlawful:
Knowingly open, lease, rent, use, or maintain any place, whether permanently or temporarily, for the purpose of manufacturing, distributing, or using any controlled substance;
Manage or control any place, whether permanently or temporarily, either as an owner, lessee, agent, employee, occupant, or mortgagee, and knowingly and intentionally rent, lease, profit from, or make available for use, with or without compensation, the place for the purpose of unlawfully manufacturing, storing, distributing, or using a controlled substance [52].
Based on the Crack House Statute, it is illegal to run a facility where controlled substances, such as opioids, are used. With this statute, operating these facilities is considered a federal crime and individuals can be subject to a felony with imprisonment of up to 20 years, and hundreds of thousands of dollars in fines [52]. With McSwain’s civil lawsuit against Safehouse, it now became up to the federal courts to decide if safe injection sites indeed violate the Crack House Statute. McSwain in conjunction with the Justice Department argued that the plain language of the law was clear, and if advocates of Safehouse wanted to change the law to open safe injection sites, they would have to lobby Congress [53]. On the other hand, advocates for Safehouse argued that the Crack House Statute does not apply to safe injection sites as the law only intended to impact the owners and tenants of drug dens at a time when the crack-cocaine epidemic was at its height [53]. Despite McSwain’s appeal, in October 2019, U.S. District Judge Gerald A. McHugh did not believe the Crack House Statute applied to safe injection sites, such as Safehouse, as he did not believe that lawmakers had safe injection sites in mind when creating the Controlled Substances Act [53]. McHugh further argued that the goal of safe injection sites, such as Safehouse, is to “reduce drug use, not facilitate it, and that it was up to Congress to amend the statute if it wanted to deem safe injection [53].
After this initial victory defending the implementation of safe injection sites, the battle over the legality of safe injection sites has continued. On February 25, 2020, McHugh issued a Final Declaratory Judgement for Safehouse which declared that the proposed safe injection site did not violate any of the federal drug laws [50]. Safehouse asked for this judgment to be assured that they could proceed with their plans to open a proposed safe injection site [54]. With this reaffirmation of the legality of safe injection sites, Safehouse was ready to bring the first safe injection site inside the Constitution Health Plaza at the corner of Broad and McKean Street in South Philadelphia [54]. However, McSwain adamantly continued his argument against the implementation of safe injections sites under the current law, and appealed McHugh’s decision to the U.S. Court of Appeals for the Third Circuit a few days after McHugh’s final judgment [55]. McSwain also asked for an Emergency Motion of Stay, which would prevent safe injection sites from opening until the Third Circuit court made its decision [50]. Along with McSwain, community residents in South Philadelphia resisted the idea of safe injection sites. Residents argued that crime would be brought to their neighborhoods, and that safe injection sites were not going to solve the opioid epidemic [56].
Despite the resistance, Safehouse did not want to slow the progress they had made. On March 10, 2020, in response to McSwain’s order for a stay to be issued, Safehouse requested that a stay not be issued on the case [50]. However, during the following week, the city of Philadelphia went into lockdown due to the COVID-19 pandemic, resulting in the closure of courts across the Philadelphia area [57]. Along with the COVID-19 pandemic, protests against police brutality swept across the nation after the killing of Mr. George Floyd in late May 2020 [58]. With city and country officials being overwhelmed with the challenges associated with COVID-19 and the outrage over police brutality, McHugh ultimately decided to approve McSwain’s emergency stay on June 25, 2020 [58]. Even though McHugh did not change his original verdict on safe injection sites, he believed it was the “wrong moment for another change in the status quo” [58]. After a long delay, a three-member panel of the Third Circuit Court of Appeals eventually started hearing oral arguments on November 16, 2020 [50]. At the conclusion of the case hearing, the Third Circuit Court of Appeals agreed with the Government that supervised safe injection sites are illegal under federal law on January 13, 2021 [59]. In a 2-1 decision, the appeals court decided to change to the decision of the federal district court as it argued that Safehouse “knows and intends that visitors to its consumption room will have a significant purpose of using illegal drugs” [59]. With this decision, Safehouse suffered a massive blow, as opening safe injection sites became declared to be illegal in the United States. On February 24, 2021, Safehouse filed a Petition for Rehearsing En Banc, which requested a rehearsal in front of the entire panel, but this request was denied on March 24, 2021, despite three judges issuing strong dissents to the denial [50]. Safehouse still has options to appeal to the Supreme Court of the United States.
With the promise of a ruling on safe injection sites going to the Supreme Court of the United States, several states have continued to lobby for state laws that support the implementation of safe injection sites. For example, after first introducing the idea of Harm Reduction Centers in 2019, lawmakers revised two versions of a bill known as H 5245 and S 0016, which focus on the creation of a harm reduction center advisory committee and pilot program [60]. The Senate version of the bill, S 0016, which was passed on February 23, 2021, would result in the establishment of an advisory committee that makes recommendations to the state’s Health Department Director on the regulation of safe injection sites. Unlike the house version, the Senate version of the bill provides liability protection that prevents “property owners, managers, employees, volunteers, clients, or participants, and state, city, or town government employees acting in the course and scope of employment” from being arrested or prosecuted [60]. If the house version of the bill, H 5245, is passed by the house and approved by Rhode Island Governor Gina Raimondo, Rhode Island could be the first state to legalize safe injection sites [60].
Along with Rhode Island, on March 2, 2021, the New Mexico House passed HB 123, a bill authorizing counties to establish and operate OPPs (Overdose Prevention Programs) following guidelines that will be created by the New Mexico Department of Health by October 1 [61]. In the argument for the creation of OPPs, lawmakers took a similar legal stance to the proponents of Safehouse and argued that the purpose of these sites is to protect the health of people who do drugs, not to facilitate drug use [61]. If the legislation passes through the New Mexico State Senate, OPPs will be established in New Mexico. Despite the ruling against Safehouse in January 2021, state legislatures remain optimistic that their versions of safe injection sites will be federally legal, as President Biden has strongly emphasized the key component of harm reduction in his National Drug Control Policy. The Biden-era Office of National Drug Control Policy (ONDCP), places a great emphasis on “confronting racial equity issues related to drug policy” and “enhancing evidence-based harm reduction efforts” [62]. With strong support for harm reduction in combating drug abuse by the President, the legal approval of safe injection sites seems to be on the horizon.
While safe injection sites carry tremendous potential benefits, there are also some important risks. Outside of the legal issues previously discussed, one main potential risk of safe injection sites proposed by critics is that they can encourage drug use and disincentive drug cessation by sending out the message that drug use is legally tolerable [46]. One study on Insite in Vancouver measured changes in drug use among PWID in Vancouver both one year before and after Insite was opened. This study showed that there were no significant differences in rates of relapse into injected drug use (17% versus 20%), or stopping injected drug use (17% versus 15%) [63]. In addition, the study showed that there were no significant differences in crack cocaine smoking (12% versus 14%), rates of stopping methadone use (11% versus 7%) or starting methadone use (13% versus 11%), and rates of stopping binge drug use (58% versus 63%) [63]. The opening of Insite clearly did not significantly affect community drug use or drug cessation. In addition, another study examined drug injection cessation between December 2003 and June 2006 in Vancouver after the opening of Insite with a sample of over 1090 participants, and it was found that 46% of participants entered into treatment [64]. Based on this study, drug injection cessation does not appear to decrease or be disincentivized as a result of opening up safe injection site facilities, such as Insite, as PWID entered treatment to stop drug use.
Along with potential increases in drug use and the disincentivizing of drug cessation, another potential risk of safe injection sites voiced by critics is that these sites increase crime and neighborhood disorder. In a study comparing annual periods before and after the opening of Insite in Vancouver, it was found that rates of drug trafficking, assaults, and robbery were similar after Insite’s opening [65]. Based on this study, neighborhood crime rates have not significantly increased or decreased as a result of opening safe injection sites, such as Insite. Similar to the trends in crime rates, there has been no evidence to show that safe injection sites increase neighborhood disorder. In a study comparing public injection drug use and public syringe disposal before and 12-weeks after the opening of Insite, there were statistically significant reductions in the daily mean number of injecting drug users injecting in public from approximately 4.3 users to 2.4 users and significant reductions in publicly discarded syringes from a daily average of 11.5 to 5.3 syringes [66]. This study also showed that there was a statistically significant reduction in injection-related litter for Insite as the pre/post daily mean count of injection-related litter decreased from 601.7 to 305.3 [66]. Based on this study, safe injection sites do not appear to increase neighborhood disorder. Moreover, critics of safe injection sites have also feared that these sites will promote drug tourism from outside of the community [46]. Despite the evidence showing that increases in crime rates and neighborhood disorder are unlikely, no studies are currently available that have analyzed the potential problem of drug tourism. However, scholars have pointed out that the majority of PWID users are residents in the area surrounding the safe injection Insite, so it would be unlikely that after the implementation of Insite people would travel long distances just to use drugs in a dangerous and impoverished area of Vancouver [46].
While crime rates, neighborhood disorder, and drug tourism seem unlikely to increase as a result of safe injection sites, continued potential risk of safe injection sites is the lack of community support for them. For example, South Philadelphia residents felt “blindsided” by Safehouse’s decision to plan a safe injection site in South Philadelphia, and accused Safehouse of never soliciting the community’s support [49]. Many residents located near potential safe injection sites fear the potential for increases in crime and neighborhood disorder with some completely rejecting the notion that safe injection sites can even mitigate the opioid epidemic. However, one study analyzing community perceptions of neighborhood disorder 5 years after the opening of the Uniting Medically Supervised Injecting Centre (MISC) in Australia, showed that the fears of residents seem to dissipate over time [67]. In this study, business owners and residents in the surrounding area of MISC noted that they had witnessed lower instances of public injecting and publicly discarded injecting equipment [67]. Over 90% of participants in this study also reported at least one advantage of MISC in their area [67]. Even though community support of safe injection sites tends to increase over time, it appears to be important to consult the community of proposed safe injection site locations to educate the members about the benefits and potential risks. This education could potentially make residents more understanding of safe injection sites from the start of their implementation.
According to critics, another potential risk of safe injection sites is that they will fail as PWID do not even want to quit injecting drugs to begin with. Scholars have argued that critics who have this viewpoint presuppose that PWID are “completely void of any desire to quit the drug habit, or that the PWID evaluate their desire to stay addicted so positively that the desire to quit is an insignificant element in their decision-making process” [46]. In a scenario like Insite where drug addiction is strong for users, it is false that PWID are completely void of any desires as addicted people experience a conflict between the desire to stay addicted and the desire to do away with drugs and start a normal life [46]. In addition, scholars believe that the view that the desire to quit is an insignificant element for PWID is false, as it implies that PWID enjoy a low quality of life along with the drug-induced euphoria they experience [46]. It is unreasonable to think that PWID enjoy their low quality of life filled with homelessness and violence in many cases. In a study of 42 PWID evaluating their perceptions of safe injection sites, several participants felt that safe injection sites would improve their neighborhoods through a lessened community exposure to drug use and less injection equipment on the streets [68]. Clearly, many PWID want to escape their life of drugs but need a facility, such as a safe injection site, to help overcome their addiction.
Along with the risk of safe injection sites failing based on the belief that PWID do not want to stop injecting drugs, safe injection sites also have financial implications. Unlike Canada where the operating costs of Insite have been provided by the British Columbia Ministry of Health Services and additional funding has been provided by Health Canada, cities in the United States are not currently funding safe injection sites [69]. Since the city of Philadelphia is not funding safe injection sites, many individuals rightfully question how these facilities will be funded and maintained. Before the potential opening of Safehouse in February 2020, Safehouse only had $200,000 in the bank, which was tremendously less than the estimated annual $1 million operating costs of the facility [54]. However, recently in March 2021, the $1.9 trillion American Rescue Plan Act was enacted, which allocated $4 billion to address the overdose crisis in America and face the challenges of substance use disorder and mental health [70]. Of the $4 billion, $30 million was allocated to “support community-based overdose prevention programs, syringe service programs, and other harm reduction services” [50]. This commitment to harm reduction may set the stage for funding for safe injection sites in the long term, although the funding of safe injection is still currently in the hands of private donors in the case of safe injection sites, such as Safehouse.
The development of safe injection sites as a solution to the devasting opioid crisis in the United States has caused a tremendous debate amongst individuals from a wide variety of backgrounds. As previously discussed, the advantages of safe injection sites are extensive. Safe injection sites have been shown to successfully manage on-site overdoses, reduce drug-related overdose death rates, reduce the risk behavior associated with HIV and Hepatitis C, increase the delivery of medical and social services, and increase the number of individuals entering into substance use disorder treatment. In addition, further advantages of safe injection sites include reducing the amount and frequency individuals use drugs, along with saving costs via reducing the prevalence of diseases, overdose deaths, and the need for emergency medical services. While safe injection sites, such as Insite, have clearly been shown to be cost-effective and successful in combating the opioid crisis in Vancouver, safe injection sites are not without their concerns. Critics of safe injection sites highlight concerns of increased drug use, crime, neighborhood disorder and drug tourism, reduced drug cessation, and the notion that safe injection sites will fail as PWID do not even want to quit drugs to begin with. Furthermore, critics have concerns about the potential lack of community support, how safe injection sites will be funded, and the legality behind them.
While these concerns have been previously discussed, one notion of the argument that seems to be missing is the ethical implications of safe injection sites. Are safe injection sites even ethical to begin with? Clearly, it would not be advisable to support a project that is unethical in nature, even despite the end result of the means. Even if safe injections sites provide the end result of mitigating the opioid crisis, they simply cannot be unethical in nature if they are to be successfully instituted in the United States. To determine if safe injection sites are ethical, the Catholic social teaching principles of respect for human dignity, solidarity, the common good, and the stewardship of resources will be applied to safe injection sites. The relationship of safe injection sites to the harm reduction theory will also be elaborated on to evaluate the ethics of safe injection sites.
The principle of human dignity is known as the foundational principle for Catholic social teaching. The United States Conference of Catholic Bishops describes the principle of human dignity as the following:
As expressed in this principle, every human being, from their conception to their death has inherent dignity and right to life based on that dignity. In practice, every human being, regardless of their personal race, religion, sex, age, national origin, sexual orientation, economic status, health, intelligence, or any other characteristic that differentiates individuals from one another, is worthy of respect [72]. Despite differing characteristics between individuals, simply being a human being confers one this dignity. As a result of this dignity, the human person is always seen as an end in the Catholic view, not as a means. The presence of human dignity further guarantees every human person a claim of membership in a community known as the human family.
Applying the respect for human dignity to safe injection sites, all individuals, especially PWID, have an inherent value to their lives that must be respected. Despite using drugs, PWID are equal to every other human person in that their dignity must be safeguarded at all times. PWID are part of the vulnerable group of individuals across the world known as the invisible and dispensable minority. As a result, PWID are often stereotyped as less valuable members of society, and their dignity is overlooked. Safe injection sites respect the dignity of PWID by directly reducing drug use, drug overdose deaths, and diseases, all of which if left unattended would directly threaten the inherent value of each PWID’s life. By helping to encourage PWID into substance use disorder treatment and giving them medical and social services, safe injections sites actually enhance the respect for human dignity for PWID by protecting these individuals’ lives. Safe injection sites ultimately accept PWID for who they are and where they are at the present moment.
The principle of solidarity at its core functions is to promote peace and justice for all, along with protecting the common good. The United States Conference of Catholic Bishops describes the principle of solidarity as the following:
As evident by this principle, every human being is part of one family known as the human family. Despite our national origins or any social, political, or economic barriers that separate us, every human being is interconnected with one another. Promoting solidarity for all involves a commitment to every human being that you will seek peace and justice for everyone and promote the common good. The principle of solidarity is grounded in the Gospels’ calls for human beings to be peacemakers, and Pope Paul VI has elaborated on this notion by stating that “if you want peace, work for justice” [73]. Solidarity ultimately facilitates peace, justice, and the common good for all.
Despite this sense of togetherness across the globe, solidarity has been threatened by the lack of concern for the poor and the most vulnerable individuals in society. The United States Bishops have even promoted the notion that more attention should be provided to “the needs of the poor, the weak, and the vulnerable, in a debate often dominated by more powerful interests” [71]. In terms of PWIDs, these individuals are part of the vulnerable, poor, and weak in society. PWIDs often lack social support and financial resources to overcome their addiction to the drug, leading them to continue in a constant cycle of addiction. Safe injection sites promote solidarity by emphasizing a preferential option for the poor and vulnerable by giving them adequate care and resources to overcome their addiction. While others may look down upon PWIDs, safe injection sites graciously accept them for the human beings they are and seek to invoke unity to overcome their addiction together. Safe injection sites are a direct commitment to the global community to reduce human suffering and ensure the value of human dignity for all.
The principle of the common good is an essential ethical imperative in Catholic social teaching. The United States Conference of Catholic Bishops describes the principle of the common good as the following:
Based on this definition, the common good is inevitability linked to solidarity and human dignity. The social conditions that promote the common good presume the “respect for the person,” “the social well-being and development of the group,” and the maintenance by a public authority that promotes the ideals of peace and justice [72]. Without the foundational pillars of solidarity and human dignity, there would be no common good. In addition, the common good implies the good of all and every individual, which should be sought together collectively. However, this notion of the common good directly contrasts with utilitarianism’s promotion of the greatest good for the greatest number. This utilitarian belief accepts the presence of a minority group always being injured, while the common good promotes equal treatment for all human persons. Since we are a global family of brothers and sisters, we all have a right and a duty to participate in society to seek the common good and well-being of all, especially for the poor and the most vulnerable individuals in society [71]. The Catholic Church emphasizes that the major role of governments and institutions is to protect human life and human dignity and to promote the common good [71].
With the presence of global interdependence in contemporary times, the principle of the common good emphasizes the “need for international structures that can promote the just development of the human family across regional and national lines” [72]. Since it is the government’s duty to promote the common good for all, including PWID, the creation of safe injection sites would support the goal of addressing the needs of the most vulnerable and poor in society. As a community with inherently valuable lives, we have a duty to support PWID. Reducing drug use, drug overdose deaths, and disease are all clear components of the common good that promote the inherent value of human life and are a preferential option for the poor and vulnerable. The common good could easily be promoted by governments in this case with the development of facilities, such as safe injection sites, that seek to combat the devastation of drug use, which affects the human person, and as a result, the global human community.
The principle of stewardship is one that emphasizes the value of management, not ownership. The United States Conference of Catholic Bishops describes the principle of stewardship as the following:
Using this definition of stewardship, it is evident that a key role in Catholic social teaching is to protect the people and planet that God created. Since we are all created in the image of God, we not only have a moral responsibility to the environment, but also to our personal talents, personal health, and our use of the private property [72]. The principle of stewardship, therefore, contains the stewardship of resources, which in itself emphasizes a just allocation of resources in the world. This requirement for the just allocation of resources has tremendous implications for safe injection sites. For example, safe injection sites fulfill the duty of the stewardship of resources by providing a just allocation of healthcare resources. Safe injections sites, such as CUES discussed above, provide health care services, such as wound care, pregnancy tests, immunizations, recovery/detoxification services, referrals to treatment, and on-site overdose care to PWID, who are some of the most vulnerable individuals in society. By justly allocating healthcare resources to PWID, the principle of the stewardship of resources is effectively and adequately promoted. Furthermore, safe injection sites, such as CUES, provide the vulnerable with equitable access to food and housing, which PWID would not have adequate access to without these facilities. Providing basic necessities and rights to individuals, such as the right to healthcare and safe injection sites, are improving the lives of individuals, which in turn improves the overall well-being of the interconnected global community. Moreover, the more general principle of stewardship is applicable to safe injection sites through their ability to reduce waste in the environment. As previously described, safe injection sites reduce the number of drug injecting equipment waste present in the community, which further fulfills the goal of stewardship in promoting respect for God’s creation.
The driving ethical force behind the push for safe injection sites like CUES to be made available as a viable option for PWID is their potential to be used under the harm reduction idea. Harm reduction is an approach focused on minimizing the negative results that go hand-in-hand with drug abuse [74, 75]. Harm reduction techniques have both a medical and ethical impact on the individual and society as a whole. Harm reduction techniques accept the individuals as they are, while also tailoring that person’s treatment to fit his or her needs [76]. Furthermore, there are certain principles that are quintessential to an understanding of harm reduction, as listed by the Harm Reduction Coalition:
Accepts, for better and/or worse, that licit and illicit drug use is part of our world and chooses to work to minimize its harmful effects rather than simply ignore or condemn them.
Understands drug use as a complex, multi-faceted phenomenon that encompasses a continuum of behaviors from severe abuse to total abstinence and acknowledges that some ways of using drugs are clearly safer than others.
Establishes quality of individual and community life and well-being–not necessarily cessation of all drug use–as the criteria for successful interventions and policies.
Calls for the non-judgmental, non-coercive provision of services and resources to people who use drugs and the communities in which they live to assist them in reducing attendant harm.
Ensures that drug users and those with a history of drug use routinely have a real voice in the creation of programs and policies designed to serve them.
Affirms drugs users themselves as the primary agents of reducing the harms of their drug use and seeks to empower users to share information and support each other in strategies that meet their actual conditions of use.
Recognizes that the realities of poverty, class, racism, social isolation, past trauma, sex-based discrimination, and other social inequalities affect both people’s vulnerability to and capacity for effectively dealing with drug-related harm.
Does not attempt to minimize or ignore the real and tragic harm and danger associated with licit and illicit drug use [74].
The CUES’ ability to allow PWID to have a safe environment to inject drugs gives itself the potential to be used as a harm reduction agent in and of itself. Furthermore, many individuals who die from opiate overdoses, such as heroin, did not receive the necessary medical treatment in time to save them; allowing PWIDs access to the CUES could possibly save many preventable deaths. If we, as a society, value human life as sacred, we must find a way to prevent these deaths. The CUES program, such as Insite in Vancouver, supervised by trained medical personnel as a harm reduction agent could present a viable alternative to address the growing heroin addiction epidemic and save thousands of lives. The heroin epidemic is growing, fatal overdoses are increasing, and people are becoming more and more frustrated by legal and political barriers to new forms of treatment being put in place to stop this problem. As shown above, SIFs like Insite have been shown to decrease heroin abuse, disease, and mortality rate in Canada and Europe. In the United States, overdoses have led to 45,000 opioid overdose deaths in a 12-month period that ended in September 2017. This number is unacceptable by any standards [77]. Therefore, the harm reduction initiatives like Insite and a CUES must be introduced.
Safe injection sites are emerging as both an effective and ethical solution to the opioid crisis in the United States. However, to deal with the various concerns about safe injection sites along with the potential for additional benefits, this article seeks to make a variety of recommendations concerning the implementation of safe injection sites. These seven recommendations include legal, medical, educational, social, and financial implications that seek to make safe injection sites as effective as possible in the United States.
Legal: Mobile and portable units like a van could be used as safe injection sites to overcome the Crack House Statute. Even McSwain himself, a staunch critic of safe injection sites, acknowledged that mobile units would not be a violation of the Crack House Statute [78]. Since mobile and portable units do not pertain to real estate, McSwain does not think the Crack House Statute applies to them. Prevention Point Philadelphia already uses vans effectively for their clean needle exchange program.
Educational: Provide medical residents, physician assistants, nurse practitioners, and medical students the opportunity to do rotations at safe injection sites. This would allow these medical professionals to be educated on communication skills with vulnerable populations, which is often not addressed in medical education programs. The opportunity to do rotations would also give medical professionals a better sense of cultural sensitivity, further allowing these individuals to have a more holistic understanding of medicine.
Medical: Mandatory fentanyl testing at all safe injection site facilities to protect PWID. As discussed previously, fentanyl is over 50–100 times more potent than morphine and is becoming increasingly prevalent in cities such as Philadelphia. If we really care about PWID and want to respect their human dignity and their lives, then we should seek to mitigate the extremely dangerous risk of injecting opioids laced with fentanyl.
Social: Safe injection sites should provide social support services such as housing, employment, and job development counseling. This would help PWID escape their addiction lifestyle, and give them skills and knowledge to be successful and productive members of society.
Social: Create an advisory board to combat the concern of the lack of community involvement in the implementation of safe injection sites in various communities. This advisory board would be a diverse group consisting of medical professionals, community leaders, social workers, addiction counselors, and clergy.
Medical/Social: Preferably utilize addiction counselors who have been former addicts as they have a deeper relationality to PWID, which will allow them to treat PWID for who they are and where they are at in the present moment. These addiction counselors have walked the walked and talked the talk, which will enhance the rehab counseling experience.
Financial: No city funding should be put toward safe injection sites, as the use of tax dollars for safe injection sites would likely be extremely controversial. Instead, we recommend that safe injection sites rely on funding from grants and nonprofits, and potential partnerships with one to two local health systems. In Philadelphia, the five main health systems include Jefferson Health, The University of Pennsylvania Health System, Tower Health, Temple Health, and Trinity Health. Safe injection sites have been proved to be cost-effective and save medical resources by reducing the number of emergency room visits and the need for emergency services. As a result, partnering with safe injection sites could save healthcare systems money, and be a cheaper alternative than the expensive use of emergency medical resources.
With these recommendations, safe injection sites could legally and effectively open in cities across the United States with the aim of mitigating the devastation that the opioid epidemic has caused in the country for the last three decades.
IntechOpen books are published online and are accessible for free.
\r\n\r\nHowever, if you are interested in ordering your hardcover copy, you can do so by contacting our Print Sales Department at orders@intechopen.com. All IntechOpen books are printed on demand in full-colour and delivered in signature packaging through FREE DHL Express delivery.
\r\n\r\nFor a quote or assistance please contact us directly at orders@intechopen.com The quote will be sent to you within 1-2 business days.
\r\n\r\nOur entire portfolio of over 5,500 books is also available through Amazon.
',metaTitle:"Order and delivery",metaDescription:"Our books are published online and are accessible for free. However, if you are interested in ordering your hardcover copy, you can do so by contacting our Print Sales Department at orders@intechopen.com. All IntechOpen books are printed on demand in full-colour and delivered in signature packaging through free DHL Express delivery. A selection of our books in soft cover is also available through Amazon.",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"Our books are available hardcover, printed in full colour and produced to the highest standards on PEFC™ and FSC certified paper, complying with principles of responsible forestry worldwide. The paper size is 180 x 260 mm (7 x 10.2 inches).
\\n\\nIntechOpen works with award winning print-houses and we hold to the fact that all of our printed products are of the highest quality.
\\n\\nIntechOpen books retail price range is:
\\n\\n100 - 159 GBP ex. VAT (available in USD and EUR)
\\n\\nDiscounts available:
\\n\\nBulk discounts are granted for orders of 10 copies and more.
\\n\\nThere is no minimum or maximum threshold on the quantity of book orders.
\\n\\nOrders have to be paid in advance and before printing. We accept payment in GBP, EUR and USD.
\\n\\nWe currently accept the following payment options:
\\n\\nWhen paying with a credit card, you will be redirected to the PayPal.com online payment portal.
\\n\\nIntechOpen will help you complete your payment safely and securely, keeping your personal, professional and financial information safe.
\\n\\nIn accordance with the best security practice, we do not accept card orders via email.
\\n\\nThe combined printing and delivery time for orders vary from 7-15 business days, depending on the printed quantity and destination. This period does not include any customs clearance difficulties that may arise and that are beyond our control. Once your order has been printed and shipped, you will receive a confirmation email that includes your DHL tracking number. You can then track your order at www.dhl.com.
\\n\\nIf you do not receive your order within 30 days from the date your order is shipped, please contact us to inquire about the shipping status at orders@intechopen.com.
\\n\\nTax: Residents of European Union countries need to add a Book Value-Added Tax Rate based on their country of residence. Institutions and companies, registered as VAT taxable entities in their own EU member state, will not pay VAT by providing IntechOpen with their VAT registration number. This is made possible by the EU reverse charge method.
\\n\\nCustoms: free shipping does not include any duties, taxes or clearing charges levied by the destination country. These charges are the responsibility of the customer and will vary from country to country.
\\n\\nP.O. Boxes cannot be used as a Ship-To Address.
\\n\\nIntechOpen partners do not provide shipping service from Europe to the countries listed below. Please refrain from mailing items addressed to the countries listed below, until further notice.
\\n\\nWhen ordering our books from the countries listed below, please provide an alternative mailing address. For any further assistance, please contact us at orders@intechopen.com.
\\n\\nRestricted Ship-to Countries:
\\n\\nPOD products are non-returnable and non-refundable, except in the event of poor print quality or an error in quantity. If we delivered the item to you in error or the item is faulty, please contact us.
\\n\\nInspect your order carefully when it arrives. Any problems should be immediately reported to orders@intechopen.com.
\\n\\nPrint copies of our publications are most often purchased by universities, libraries, institutions and academia personnel, hence increasing the visibility and outreach of our authors' published work among science communities and institutions.
\\n\\nOur books are available at our direct Print Sales Department and through selected representatives throughout the world.
\\n\\nBooks International
\\n\\nRepresentative for: Brunei, Cambodia, Indonesia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam (ASEAN)
\\n\\nChina Publishers Services Ltd - CPS
\\n\\nRepresentative for: China, Taiwan, Hong Kong
\\n\\nIndia - CBS Publishers & Distributors Pvt. Ltd.
\\n\\nRepresentative for: India, Bangladesh, Pakistan, Sri Lanka, Bhutan, Nepal, Maldives, Iran, Algeria, Bahrain, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Malta, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunis, United Arab Emirates and Yemen
\\n\\nLSR Libros Servicios y Representaciones S.A. de C.V
\\n\\nRepresentative for Mexico, Chile and Colombia
\\n\\nMissing Link Versandbuchhandlung eG
\\n\\nRepresentative for: Germany, Austria, Switzerland
\\n\\nKuba Libri, s.r.o.
\\n\\nRepresentative for: Czech Republic
\\n\\nFor partnership opportunities, please contact orders@intechopen.com.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Our books are available hardcover, printed in full colour and produced to the highest standards on PEFC™ and FSC certified paper, complying with principles of responsible forestry worldwide. The paper size is 180 x 260 mm (7 x 10.2 inches).
\n\nIntechOpen works with award winning print-houses and we hold to the fact that all of our printed products are of the highest quality.
\n\nIntechOpen books retail price range is:
\n\n100 - 159 GBP ex. VAT (available in USD and EUR)
\n\nDiscounts available:
\n\nBulk discounts are granted for orders of 10 copies and more.
\n\nThere is no minimum or maximum threshold on the quantity of book orders.
\n\nOrders have to be paid in advance and before printing. We accept payment in GBP, EUR and USD.
\n\nWe currently accept the following payment options:
\n\nWhen paying with a credit card, you will be redirected to the PayPal.com online payment portal.
\n\nIntechOpen will help you complete your payment safely and securely, keeping your personal, professional and financial information safe.
\n\nIn accordance with the best security practice, we do not accept card orders via email.
\n\nThe combined printing and delivery time for orders vary from 7-15 business days, depending on the printed quantity and destination. This period does not include any customs clearance difficulties that may arise and that are beyond our control. Once your order has been printed and shipped, you will receive a confirmation email that includes your DHL tracking number. You can then track your order at www.dhl.com.
\n\nIf you do not receive your order within 30 days from the date your order is shipped, please contact us to inquire about the shipping status at orders@intechopen.com.
\n\nTax: Residents of European Union countries need to add a Book Value-Added Tax Rate based on their country of residence. Institutions and companies, registered as VAT taxable entities in their own EU member state, will not pay VAT by providing IntechOpen with their VAT registration number. This is made possible by the EU reverse charge method.
\n\nCustoms: free shipping does not include any duties, taxes or clearing charges levied by the destination country. These charges are the responsibility of the customer and will vary from country to country.
\n\nP.O. Boxes cannot be used as a Ship-To Address.
\n\nIntechOpen partners do not provide shipping service from Europe to the countries listed below. Please refrain from mailing items addressed to the countries listed below, until further notice.
\n\nWhen ordering our books from the countries listed below, please provide an alternative mailing address. For any further assistance, please contact us at orders@intechopen.com.
\n\nRestricted Ship-to Countries:
\n\nPOD products are non-returnable and non-refundable, except in the event of poor print quality or an error in quantity. If we delivered the item to you in error or the item is faulty, please contact us.
\n\nInspect your order carefully when it arrives. Any problems should be immediately reported to orders@intechopen.com.
\n\nPrint copies of our publications are most often purchased by universities, libraries, institutions and academia personnel, hence increasing the visibility and outreach of our authors' published work among science communities and institutions.
\n\nOur books are available at our direct Print Sales Department and through selected representatives throughout the world.
\n\nBooks International
\n\nRepresentative for: Brunei, Cambodia, Indonesia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam (ASEAN)
\n\nChina Publishers Services Ltd - CPS
\n\nRepresentative for: China, Taiwan, Hong Kong
\n\nIndia - CBS Publishers & Distributors Pvt. Ltd.
\n\nRepresentative for: India, Bangladesh, Pakistan, Sri Lanka, Bhutan, Nepal, Maldives, Iran, Algeria, Bahrain, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Malta, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunis, United Arab Emirates and Yemen
\n\nLSR Libros Servicios y Representaciones S.A. de C.V
\n\nRepresentative for Mexico, Chile and Colombia
\n\nMissing Link Versandbuchhandlung eG
\n\nRepresentative for: Germany, Austria, Switzerland
\n\nKuba Libri, s.r.o.
\n\nRepresentative for: Czech Republic
\n\nFor partnership opportunities, please contact orders@intechopen.com.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"396",title:"Dr.",name:"Vedran",middleName:null,surname:"Kordic",slug:"vedran-kordic",fullName:"Vedran Kordic",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/396/images/7281_n.png",biography:"After obtaining his Master's degree in Mechanical Engineering he continued his education at the Vienna University of Technology where he obtained his PhD degree in 2004. He worked as a researcher at the Automation and Control Institute, Faculty of Electrical Engineering, Vienna University of Technology until 2008. His studies in robotics lead him not only to a PhD degree but also inspired him to co-found and build the International Journal of Advanced Robotic Systems - world's first Open Access journal in the field of robotics.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"441",title:"Ph.D.",name:"Jaekyu",middleName:null,surname:"Park",slug:"jaekyu-park",fullName:"Jaekyu Park",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/441/images/1881_n.jpg",biography:null,institutionString:null,institution:{name:"LG Corporation (South Korea)",country:{name:"Korea, South"}}},{id:"465",title:"Dr.",name:"Christian",middleName:null,surname:"Martens",slug:"christian-martens",fullName:"Christian Martens",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Rheinmetall (Germany)",country:{name:"Germany"}}},{id:"479",title:"Dr.",name:"Valentina",middleName:null,surname:"Colla",slug:"valentina-colla",fullName:"Valentina Colla",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/479/images/358_n.jpg",biography:null,institutionString:null,institution:{name:"Sant'Anna School of Advanced Studies",country:{name:"Italy"}}},{id:"494",title:"PhD",name:"Loris",middleName:null,surname:"Nanni",slug:"loris-nanni",fullName:"Loris Nanni",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/494/images/system/494.jpg",biography:"Loris Nanni received his Master Degree cum laude on June-2002 from the University of Bologna, and the April 26th 2006 he received his Ph.D. in Computer Engineering at DEIS, University of Bologna. On September, 29th 2006 he has won a post PhD fellowship from the university of Bologna (from October 2006 to October 2008), at the competitive examination he was ranked first in the industrial engineering area. He extensively served as referee for several international journals. He is author/coauthor of more than 100 research papers. He has been involved in some projects supported by MURST and European Community. His research interests include pattern recognition, bioinformatics, and biometric systems (fingerprint classification and recognition, signature verification, face recognition).",institutionString:null,institution:null},{id:"496",title:"Dr.",name:"Carlos",middleName:null,surname:"Leon",slug:"carlos-leon",fullName:"Carlos Leon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Seville",country:{name:"Spain"}}},{id:"512",title:"Dr.",name:"Dayang",middleName:null,surname:"Jawawi",slug:"dayang-jawawi",fullName:"Dayang Jawawi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"528",title:"Dr.",name:"Kresimir",middleName:null,surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/528/images/system/528.jpg",biography:"K. Delac received his B.Sc.E.E. degree in 2003 and is currentlypursuing a Ph.D. degree at the University of Zagreb, Faculty of Electrical Engineering andComputing. His current research interests are digital image analysis, pattern recognition andbiometrics.",institutionString:null,institution:{name:"University of Zagreb",country:{name:"Croatia"}}},{id:"557",title:"Dr.",name:"Andon",middleName:"Venelinov",surname:"Topalov",slug:"andon-topalov",fullName:"Andon Topalov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/557/images/1927_n.jpg",biography:"Dr. Andon V. Topalov received the MSc degree in Control Engineering from the Faculty of Information Systems, Technologies, and Automation at Moscow State University of Civil Engineering (MGGU) in 1979. He then received his PhD degree in Control Engineering from the Department of Automation and Remote Control at Moscow State Mining University (MGSU), Moscow, in 1984. From 1985 to 1986, he was a Research Fellow in the Research Institute for Electronic Equipment, ZZU AD, Plovdiv, Bulgaria. In 1986, he joined the Department of Control Systems, Technical University of Sofia at the Plovdiv campus, where he is presently a Full Professor. He has held long-term visiting Professor/Scholar positions at various institutions in South Korea, Turkey, Mexico, Greece, Belgium, UK, and Germany. And he has coauthored one book and authored or coauthored more than 80 research papers in conference proceedings and journals. His current research interests are in the fields of intelligent control and robotics.",institutionString:null,institution:{name:"Technical University of Sofia",country:{name:"Bulgaria"}}},{id:"585",title:"Prof.",name:"Munir",middleName:null,surname:"Merdan",slug:"munir-merdan",fullName:"Munir Merdan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/585/images/system/585.jpg",biography:"Munir Merdan received the M.Sc. degree in mechanical engineering from the Technical University of Sarajevo, Bosnia and Herzegovina, in 2001, and the Ph.D. degree in electrical engineering from the Vienna University of Technology, Vienna, Austria, in 2009.Since 2005, he has been at the Automation and Control Institute, Vienna University of Technology, where he is currently a Senior Researcher. His research interests include the application of agent technology for achieving agile control in the manufacturing environment.",institutionString:null,institution:null},{id:"605",title:"Prof",name:"Dil",middleName:null,surname:"Hussain",slug:"dil-hussain",fullName:"Dil Hussain",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/605/images/system/605.jpg",biography:"Dr. Dil Muhammad Akbar Hussain is a professor of Electronics Engineering & Computer Science at the Department of Energy Technology, Aalborg University Denmark. Professor Akbar has a Master degree in Digital Electronics from Govt. College University, Lahore Pakistan and a P-hD degree in Control Engineering from the School of Engineering and Applied Sciences, University of Sussex United Kingdom. Aalborg University has Two Satellite Campuses, one in Copenhagen (Aalborg University Copenhagen) and the other in Esbjerg (Aalborg University Esbjerg).\n· He is a member of prestigious IEEE (Institute of Electrical and Electronics Engineers), and IAENG (International Association of Engineers) organizations. \n· He is the chief Editor of the Journal of Software Engineering.\n· He is the member of the Editorial Board of International Journal of Computer Science and Software Technology (IJCSST) and International Journal of Computer Engineering and Information Technology. \n· He is also the Editor of Communication in Computer and Information Science CCIS-20 by Springer.\n· Reviewer For Many Conferences\nHe is the lead person in making collaboration agreements between Aalborg University and many universities of Pakistan, for which the MOU’s (Memorandum of Understanding) have been signed.\nProfessor Akbar is working in Academia since 1990, he started his career as a Lab demonstrator/TA at the University of Sussex. After finishing his P. hD degree in 1992, he served in the Industry as a Scientific Officer and continued his academic career as a visiting scholar for a number of educational institutions. In 1996 he joined National University of Science & Technology Pakistan (NUST) as an Associate Professor; NUST is one of the top few universities in Pakistan. In 1999 he joined an International Company Lineo Inc, Canada as Manager Compiler Group, where he headed the group for developing Compiler Tool Chain and Porting of Operating Systems for the BLACKfin processor. The processor development was a joint venture by Intel and Analog Devices. In 2002 Lineo Inc., was taken over by another company, so he joined Aalborg University Denmark as an Assistant Professor.\nProfessor Akbar has truly a multi-disciplined career and he continued his legacy and making progress in many areas of his interests both in teaching and research. He has contributed in stochastic estimation of control area especially, in the Multiple Target Tracking and Interactive Multiple Model (IMM) research, Ball & Beam Control Problem, Robotics, Levitation Control. He has contributed in developing Algorithms for Fingerprint Matching, Computer Vision and Face Recognition. He has been supervising Pattern Recognition, Formal Languages and Distributed Processing projects for several years. He has reviewed many books on Management, Computer Science. Currently, he is an active and permanent reviewer for many international conferences and symposia and the program committee member for many international conferences.\nIn teaching he has taught the core computer science subjects like, Digital Design, Real Time Embedded System Programming, Operating Systems, Software Engineering, Data Structures, Databases, Compiler Construction. In the Engineering side, Digital Signal Processing, Computer Architecture, Electronics Devices, Digital Filtering and Engineering Management.\nApart from his Academic Interest and activities he loves sport especially, Cricket, Football, Snooker and Squash. He plays cricket for Esbjerg city in the second division team as an opener wicket keeper batsman. He is a very good player of squash but has not played squash since his arrival in Denmark.",institutionString:null,institution:null},{id:"611",title:"Prof.",name:"T",middleName:null,surname:"Nagarajan",slug:"t-nagarajan",fullName:"T Nagarajan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Teknologi Petronas",country:{name:"Malaysia"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:8616},{group:"region",caption:"Middle and South America",value:2,count:7693},{group:"region",caption:"Africa",value:3,count:3005},{group:"region",caption:"Asia",value:4,count:15646},{group:"region",caption:"Australia and Oceania",value:5,count:1284},{group:"region",caption:"Europe",value:6,count:22554}],offset:12,limit:12,total:134465},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish",topicId:"16,19,25"},books:[{type:"book",id:"11027",title:"Basics of Hypoglycemia",subtitle:null,isOpenForSubmission:!0,hash:"98ebc1e36d02be82c204b8fd5d24f97a",slug:null,bookSignature:"Dr. Alok Raghav",coverURL:"https://cdn.intechopen.com/books/images_new/11027.jpg",editedByType:null,editors:[{id:"334465",title:"Dr.",name:"Alok",surname:"Raghav",slug:"alok-raghav",fullName:"Alok Raghav"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11709",title:"Type 1 Diabetes Mellitus",subtitle:null,isOpenForSubmission:!0,hash:"cc0e61f864a2a8a9595f4975ce301f70",slug:null,bookSignature:"Dr. Shilpa Mehta and Dr. Resmy Palliyil Gopi",coverURL:"https://cdn.intechopen.com/books/images_new/11709.jpg",editedByType:null,editors:[{id:"342545",title:"Dr.",name:"Shilpa",surname:"Mehta",slug:"shilpa-mehta",fullName:"Shilpa Mehta"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11721",title:"Hypothermia and Hyperthermia - Physiology Concepts and Clinical Applications",subtitle:null,isOpenForSubmission:!0,hash:"0b0d0d929b72cece233f4b8cd014550c",slug:null,bookSignature:"Dr. Marinos Kosmopoulos",coverURL:"https://cdn.intechopen.com/books/images_new/11721.jpg",editedByType:null,editors:[{id:"442908",title:"Dr.",name:"Marinos",surname:"Kosmopoulos",slug:"marinos-kosmopoulos",fullName:"Marinos Kosmopoulos"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11889",title:"Sexual Disorders and Dysfunctions",subtitle:null,isOpenForSubmission:!0,hash:"b988fda30a4e2364ee9d47e417bd0ba9",slug:null,bookSignature:"Dr. Dhastagir Sultan Sheriff",coverURL:"https://cdn.intechopen.com/books/images_new/11889.jpg",editedByType:null,editors:[{id:"167875",title:"Dr.",name:"Dhastagir Sultan",surname:"Sheriff",slug:"dhastagir-sultan-sheriff",fullName:"Dhastagir Sultan Sheriff"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11570",title:"Influenza - New Approaches",subtitle:null,isOpenForSubmission:!0,hash:"157b379b9d7a4bf5e2cc7a742f155a44",slug:null,bookSignature:"Dr. Seyyed Shamsadin Athari and Dr. Entezar Mehrabi Nasab",coverURL:"https://cdn.intechopen.com/books/images_new/11570.jpg",editedByType:null,editors:[{id:"139889",title:"Dr.",name:"Seyyed Shamsadin",surname:"Athari",slug:"seyyed-shamsadin-athari",fullName:"Seyyed Shamsadin Athari"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11700",title:"Abdominal Trauma - New Solutions to Old Problems",subtitle:null,isOpenForSubmission:!0,hash:"8e898d70673411f9c222d429889c8967",slug:null,bookSignature:"Prof. Dmitry Victorovich Garbuzenko",coverURL:"https://cdn.intechopen.com/books/images_new/11700.jpg",editedByType:null,editors:[{id:"108808",title:"Prof.",name:"Dmitry",surname:"Garbuzenko",slug:"dmitry-garbuzenko",fullName:"Dmitry Garbuzenko"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11688",title:"Advances in Drug Delivery Methods",subtitle:null,isOpenForSubmission:!0,hash:"b237999737fb375b4f629ab01a498a9f",slug:null,bookSignature:"Prof. Bhupendra Gopalbhai Prajapati",coverURL:"https://cdn.intechopen.com/books/images_new/11688.jpg",editedByType:null,editors:[{id:"340226",title:"Prof.",name:"Bhupendra",surname:"Prajapati",slug:"bhupendra-prajapati",fullName:"Bhupendra Prajapati"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11820",title:"Acupuncture and Moxibustion - Recent Advances, New Perspectives, and Applications",subtitle:null,isOpenForSubmission:!0,hash:"e40653fa6cd3f2c653436c4e4bd8ad1e",slug:null,bookSignature:"Dr. Wen-Long Hu, Dr. Mao-Feng Sun and Dr. Yu-Chiang Hung",coverURL:"https://cdn.intechopen.com/books/images_new/11820.jpg",editedByType:null,editors:[{id:"49848",title:"Dr.",name:"Wen-Long",surname:"Hu",slug:"wen-long-hu",fullName:"Wen-Long Hu"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11566",title:"Periodontology - New Insights",subtitle:null,isOpenForSubmission:!0,hash:"75ef2eae3087ec0c7f2076cc64e2cfc3",slug:null,bookSignature:"Dr. Gokul Sridharan",coverURL:"https://cdn.intechopen.com/books/images_new/11566.jpg",editedByType:null,editors:[{id:"82453",title:"Dr.",name:"Gokul",surname:"Sridharan",slug:"gokul-sridharan",fullName:"Gokul Sridharan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11720",title:"Research and Advanced Clinical Practice in the Treatment of Osteoarthritis",subtitle:null,isOpenForSubmission:!0,hash:"f7602ad192ad1dc79a6a37ce3b461769",slug:null,bookSignature:"Prof. Hechmi Toumi and Dr. Eric Lespessailles",coverURL:"https://cdn.intechopen.com/books/images_new/11720.jpg",editedByType:null,editors:[{id:"196403",title:"Prof.",name:"Hechmi",surname:"Toumi",slug:"hechmi-toumi",fullName:"Hechmi Toumi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11598",title:"Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer",subtitle:null,isOpenForSubmission:!0,hash:"326ce75672f3a0f7ef014ba3ac7f6318",slug:null,bookSignature:"Prof. Michael Friedrich",coverURL:"https://cdn.intechopen.com/books/images_new/11598.jpg",editedByType:null,editors:[{id:"278677",title:"Prof.",name:"Michael",surname:"Friedrich",slug:"michael-friedrich",fullName:"Michael Friedrich"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11812",title:"New Insights Into Pharmacodynamics",subtitle:null,isOpenForSubmission:!0,hash:"b889e24b3132aa437b6745db36fffe9b",slug:null,bookSignature:"Prof. Mahmoud Ahmed Mansour",coverURL:"https://cdn.intechopen.com/books/images_new/11812.jpg",editedByType:null,editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:36},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:11},{group:"topic",caption:"Business, Management and Economics",value:7,count:7},{group:"topic",caption:"Chemistry",value:8,count:22},{group:"topic",caption:"Computer and Information Science",value:9,count:23},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:14},{group:"topic",caption:"Engineering",value:11,count:60},{group:"topic",caption:"Environmental Sciences",value:12,count:9},{group:"topic",caption:"Immunology and Microbiology",value:13,count:14},{group:"topic",caption:"Materials Science",value:14,count:23},{group:"topic",caption:"Mathematics",value:15,count:11},{group:"topic",caption:"Medicine",value:16,count:106},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:6},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:9},{group:"topic",caption:"Physics",value:20,count:9},{group:"topic",caption:"Psychology",value:21,count:9},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:9},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:3}],offset:12,limit:12,total:118},popularBooks:{featuredBooks:[{type:"book",id:"10858",title:"MOOC (Massive Open Online Courses)",subtitle:null,isOpenForSubmission:!1,hash:"d32f86793bc72dde32532f509b1ec5b0",slug:"mooc-massive-open-online-courses-",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/10858.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10195",title:"Serotonin and the CNS",subtitle:"New Developments in Pharmacology and Therapeutics",isOpenForSubmission:!1,hash:"7ed9d96da98233a885bd2869a8056c36",slug:"serotonin-and-the-cns-new-developments-in-pharmacology-and-therapeutics",bookSignature:"Berend Olivier",coverURL:"https://cdn.intechopen.com/books/images_new/10195.jpg",editors:[{id:"71579",title:"Prof.",name:"Berend",middleName:null,surname:"Olivier",slug:"berend-olivier",fullName:"Berend Olivier"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10755",title:"Corporate Governance",subtitle:"Recent Advances and Perspectives",isOpenForSubmission:!1,hash:"ffe06d1d5c4bf0fc2e63511825fe1257",slug:"corporate-governance-recent-advances-and-perspectives",bookSignature:"Okechukwu Lawrence Emeagwali and Feyza Bhatti",coverURL:"https://cdn.intechopen.com/books/images_new/10755.jpg",editors:[{id:"196317",title:"Associate Prof.",name:"Okechukwu Lawrence",middleName:null,surname:"Emeagwali",slug:"okechukwu-lawrence-emeagwali",fullName:"Okechukwu Lawrence Emeagwali"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11120",title:"Environmental Impact and Remediation of Heavy Metals",subtitle:null,isOpenForSubmission:!1,hash:"9e77514288e7394f1e6cd13481af3509",slug:"environmental-impact-and-remediation-of-heavy-metals",bookSignature:"Hosam M. Saleh and Amal I. Hassan",coverURL:"https://cdn.intechopen.com/books/images_new/11120.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam M.",middleName:null,surname:"Saleh",slug:"hosam-m.-saleh",fullName:"Hosam M. Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10901",title:"Grapes and Wine",subtitle:null,isOpenForSubmission:!1,hash:"5d7f2aa74874444bc6986e613ccebd7c",slug:"grapes-and-wine",bookSignature:"Antonio Morata, Iris Loira and Carmen González",coverURL:"https://cdn.intechopen.com/books/images_new/10901.jpg",editors:[{id:"180952",title:"Prof.",name:"Antonio",middleName:null,surname:"Morata",slug:"antonio-morata",fullName:"Antonio Morata"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11080",title:"Engineering Principles",subtitle:"Welding and Residual Stresses",isOpenForSubmission:!1,hash:"6c07a13a113bce94174b40096f30fb5e",slug:"engineering-principles-welding-and-residual-stresses",bookSignature:"Kavian Omar Cooke and Ronaldo Câmara Cozza",coverURL:"https://cdn.intechopen.com/books/images_new/11080.jpg",editors:[{id:"138778",title:"Dr.",name:"Kavian",middleName:"Omar",surname:"Cooke",slug:"kavian-cooke",fullName:"Kavian Cooke"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11332",title:"Essential Oils",subtitle:"Advances in Extractions and Biological Applications",isOpenForSubmission:!1,hash:"742e6cae3a35686f975edc8d7f9afa94",slug:"essential-oils-advances-in-extractions-and-biological-applications",bookSignature:"Mozaniel Santana de Oliveira and Eloisa Helena de Aguiar Andrade",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",editors:[{id:"195290",title:"Ph.D.",name:"Mozaniel",middleName:null,surname:"Santana De Oliveira",slug:"mozaniel-santana-de-oliveira",fullName:"Mozaniel Santana De Oliveira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11029",title:"Hepatitis B",subtitle:null,isOpenForSubmission:!1,hash:"609701f502efc3538c112ff47a2c2119",slug:"hepatitis-b",bookSignature:"Luis Rodrigo",coverURL:"https://cdn.intechopen.com/books/images_new/11029.jpg",editors:[{id:"73208",title:"Prof.",name:"Luis",middleName:null,surname:"Rodrigo",slug:"luis-rodrigo",fullName:"Luis Rodrigo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9537",title:"Human Rights in the Contemporary World",subtitle:null,isOpenForSubmission:!1,hash:"54f05b93812fd434f3962956d6413a6b",slug:"human-rights-in-the-contemporary-world",bookSignature:"Trudy Corrigan",coverURL:"https://cdn.intechopen.com/books/images_new/9537.jpg",editors:[{id:"197557",title:"Dr.",name:"Trudy",middleName:null,surname:"Corrigan",slug:"trudy-corrigan",fullName:"Trudy Corrigan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11371",title:"Cerebral Circulation",subtitle:"Updates on Models, Diagnostics and Treatments of Related Diseases",isOpenForSubmission:!1,hash:"e2d3335445d2852d0b906bb9750e939f",slug:"cerebral-circulation-updates-on-models-diagnostics-and-treatments-of-related-diseases",bookSignature:"Alba Scerrati, Luca Ricciardi and Flavia Dones",coverURL:"https://cdn.intechopen.com/books/images_new/11371.jpg",editors:[{id:"182614",title:"Dr.",name:"Alba",middleName:null,surname:"Scerrati",slug:"alba-scerrati",fullName:"Alba Scerrati"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11012",title:"Radiopharmaceuticals",subtitle:"Current Research for Better Diagnosis and Therapy",isOpenForSubmission:!1,hash:"f9046d6f96148b285e776f384991120d",slug:"radiopharmaceuticals-current-research-for-better-diagnosis-and-therapy",bookSignature:"Farid A. Badria",coverURL:"https://cdn.intechopen.com/books/images_new/11012.jpg",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4553},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10858",title:"MOOC (Massive Open Online Courses)",subtitle:null,isOpenForSubmission:!1,hash:"d32f86793bc72dde32532f509b1ec5b0",slug:"mooc-massive-open-online-courses-",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/10858.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:1677,editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10195",title:"Serotonin and the CNS",subtitle:"New Developments in Pharmacology and Therapeutics",isOpenForSubmission:!1,hash:"7ed9d96da98233a885bd2869a8056c36",slug:"serotonin-and-the-cns-new-developments-in-pharmacology-and-therapeutics",bookSignature:"Berend Olivier",coverURL:"https://cdn.intechopen.com/books/images_new/10195.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:1337,editors:[{id:"71579",title:"Prof.",name:"Berend",middleName:null,surname:"Olivier",slug:"berend-olivier",fullName:"Berend Olivier"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10755",title:"Corporate Governance",subtitle:"Recent Advances and Perspectives",isOpenForSubmission:!1,hash:"ffe06d1d5c4bf0fc2e63511825fe1257",slug:"corporate-governance-recent-advances-and-perspectives",bookSignature:"Okechukwu Lawrence Emeagwali and Feyza Bhatti",coverURL:"https://cdn.intechopen.com/books/images_new/10755.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:1309,editors:[{id:"196317",title:"Associate Prof.",name:"Okechukwu Lawrence",middleName:null,surname:"Emeagwali",slug:"okechukwu-lawrence-emeagwali",fullName:"Okechukwu Lawrence Emeagwali"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11120",title:"Environmental Impact and Remediation of Heavy Metals",subtitle:null,isOpenForSubmission:!1,hash:"9e77514288e7394f1e6cd13481af3509",slug:"environmental-impact-and-remediation-of-heavy-metals",bookSignature:"Hosam M. Saleh and Amal I. Hassan",coverURL:"https://cdn.intechopen.com/books/images_new/11120.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:847,editors:[{id:"144691",title:"Prof.",name:"Hosam M.",middleName:null,surname:"Saleh",slug:"hosam-m.-saleh",fullName:"Hosam M. Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10901",title:"Grapes and Wine",subtitle:null,isOpenForSubmission:!1,hash:"5d7f2aa74874444bc6986e613ccebd7c",slug:"grapes-and-wine",bookSignature:"Antonio Morata, Iris Loira and Carmen González",coverURL:"https://cdn.intechopen.com/books/images_new/10901.jpg",publishedDate:"June 15th 2022",numberOfDownloads:2273,editors:[{id:"180952",title:"Prof.",name:"Antonio",middleName:null,surname:"Morata",slug:"antonio-morata",fullName:"Antonio Morata"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11080",title:"Engineering Principles",subtitle:"Welding and Residual Stresses",isOpenForSubmission:!1,hash:"6c07a13a113bce94174b40096f30fb5e",slug:"engineering-principles-welding-and-residual-stresses",bookSignature:"Kavian Omar Cooke and Ronaldo Câmara Cozza",coverURL:"https://cdn.intechopen.com/books/images_new/11080.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:591,editors:[{id:"138778",title:"Dr.",name:"Kavian",middleName:"Omar",surname:"Cooke",slug:"kavian-cooke",fullName:"Kavian Cooke"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11332",title:"Essential Oils",subtitle:"Advances in Extractions and Biological Applications",isOpenForSubmission:!1,hash:"742e6cae3a35686f975edc8d7f9afa94",slug:"essential-oils-advances-in-extractions-and-biological-applications",bookSignature:"Mozaniel Santana de Oliveira and Eloisa Helena de Aguiar Andrade",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:515,editors:[{id:"195290",title:"Ph.D.",name:"Mozaniel",middleName:null,surname:"Santana De Oliveira",slug:"mozaniel-santana-de-oliveira",fullName:"Mozaniel Santana De Oliveira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11029",title:"Hepatitis B",subtitle:null,isOpenForSubmission:!1,hash:"609701f502efc3538c112ff47a2c2119",slug:"hepatitis-b",bookSignature:"Luis Rodrigo",coverURL:"https://cdn.intechopen.com/books/images_new/11029.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:413,editors:[{id:"73208",title:"Prof.",name:"Luis",middleName:null,surname:"Rodrigo",slug:"luis-rodrigo",fullName:"Luis Rodrigo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9537",title:"Human Rights in the Contemporary World",subtitle:null,isOpenForSubmission:!1,hash:"54f05b93812fd434f3962956d6413a6b",slug:"human-rights-in-the-contemporary-world",bookSignature:"Trudy Corrigan",coverURL:"https://cdn.intechopen.com/books/images_new/9537.jpg",publishedDate:"June 8th 2022",numberOfDownloads:2194,editors:[{id:"197557",title:"Dr.",name:"Trudy",middleName:null,surname:"Corrigan",slug:"trudy-corrigan",fullName:"Trudy Corrigan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"11371",title:"Cerebral Circulation",subtitle:"Updates on Models, Diagnostics and Treatments of Related Diseases",isOpenForSubmission:!1,hash:"e2d3335445d2852d0b906bb9750e939f",slug:"cerebral-circulation-updates-on-models-diagnostics-and-treatments-of-related-diseases",bookSignature:"Alba Scerrati, Luca Ricciardi and Flavia Dones",coverURL:"https://cdn.intechopen.com/books/images_new/11371.jpg",publishedDate:"June 23rd 2022",numberOfDownloads:341,editors:[{id:"182614",title:"Dr.",name:"Alba",middleName:null,surname:"Scerrati",slug:"alba-scerrati",fullName:"Alba Scerrati"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"11042",title:"Complementary Therapies",subtitle:null,isOpenForSubmission:!1,hash:"9eb32ccbef95289a133a76e5808a525b",slug:"complementary-therapies",bookSignature:"Mario Bernardo-Filho, Redha Taiar, Danúbia da Cunha de Sá-Caputo and Adérito Seixas",coverURL:"https://cdn.intechopen.com/books/images_new/11042.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"157376",title:"Prof.",name:"Mario",middleName:null,surname:"Bernardo-Filho",slug:"mario-bernardo-filho",fullName:"Mario Bernardo-Filho"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10037",title:"Thermoelectricity",subtitle:"Recent Advances, New Perspectives and Applications",isOpenForSubmission:!1,hash:"ad1d3f637564a29cf1636759f5401994",slug:"thermoelectricity-recent-advances-new-perspectives-and-applications",bookSignature:"Guangzhao Qin",coverURL:"https://cdn.intechopen.com/books/images_new/10037.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"188870",title:"Mr.",name:"Guangzhao",middleName:null,surname:"Qin",slug:"guangzhao-qin",fullName:"Guangzhao Qin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11357",title:"Sustainable Crop Production",subtitle:"Recent Advances",isOpenForSubmission:!1,hash:"ee41e09e4ad6a336ca9f0e5462da3904",slug:"sustainable-crop-production-recent-advances",bookSignature:"Vijay Singh Meena, Mahipal Choudhary, Ram Prakash Yadav and Sunita Kumari Meena",coverURL:"https://cdn.intechopen.com/books/images_new/11357.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"420235",title:"Dr.",name:"Vijay",middleName:null,surname:"Meena",slug:"vijay-meena",fullName:"Vijay Meena"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10863",title:"Cardiac Rhythm Management",subtitle:"Pacing, Ablation, Devices",isOpenForSubmission:!1,hash:"a064ec49b85ebfc60585c9c3690af53a",slug:"cardiac-rhythm-management-pacing-ablation-devices",bookSignature:"Mart Min and Gabriel Cismaru",coverURL:"https://cdn.intechopen.com/books/images_new/10863.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"62780",title:"Prof.",name:"Mart",middleName:null,surname:"Min",slug:"mart-min",fullName:"Mart Min"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10874",title:"Insights on Antimicrobial Peptides",subtitle:null,isOpenForSubmission:!1,hash:"23ca26025e87356a7c2ffac365f73a22",slug:"insights-on-antimicrobial-peptides",bookSignature:"Shymaa Enany, Jorge Masso-Silva and Anna Savitskaya",coverURL:"https://cdn.intechopen.com/books/images_new/10874.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"81926",title:"Dr.",name:"Shymaa",middleName:null,surname:"Enany",slug:"shymaa-enany",fullName:"Shymaa Enany"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11137",title:"Mineralogy",subtitle:null,isOpenForSubmission:!1,hash:"e0e4727c9f1f9b34d788f0dc70278f2b",slug:"mineralogy",bookSignature:"Miloš René",coverURL:"https://cdn.intechopen.com/books/images_new/11137.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"142108",title:"Dr.",name:"Miloš",middleName:null,surname:"René",slug:"milos-rene",fullName:"Miloš René"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10882",title:"Smart Drug Delivery",subtitle:null,isOpenForSubmission:!1,hash:"70c3ce4256324b3c58db970d446ddac4",slug:"smart-drug-delivery",bookSignature:"Usama Ahmad, Md. Faheem Haider and Juber Akhtar",coverURL:"https://cdn.intechopen.com/books/images_new/10882.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"255360",title:"Dr.",name:"Usama",middleName:null,surname:"Ahmad",slug:"usama-ahmad",fullName:"Usama Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10885",title:"Snake Venom and Ecology",subtitle:null,isOpenForSubmission:!1,hash:"cc4503ed9e56a7bcd9f2ca82b0c880a8",slug:"snake-venom-and-ecology",bookSignature:"Mohammad Manjur Shah, Umar Sharif, Tijjani Rufai Buhari and Tijjani Sabiu Imam",coverURL:"https://cdn.intechopen.com/books/images_new/10885.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"94128",title:"Dr.",name:"Mohammad Manjur",middleName:null,surname:"Shah",slug:"mohammad-manjur-shah",fullName:"Mohammad Manjur Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10381",title:"Electrocatalysis and Electrocatalysts for a Cleaner Environment",subtitle:"Fundamentals and Applications",isOpenForSubmission:!1,hash:"9dbafb0b297cf5cbdb220707e022a228",slug:"electrocatalysis-and-electrocatalysts-for-a-cleaner-environment-fundamentals-and-applications",bookSignature:"Lindiwe Eudora Khotseng",coverURL:"https://cdn.intechopen.com/books/images_new/10381.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"236596",title:"Dr.",name:"Lindiwe Eudora",middleName:null,surname:"Khotseng",slug:"lindiwe-eudora-khotseng",fullName:"Lindiwe Eudora Khotseng"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10900",title:"Prunus",subtitle:"Recent Advances",isOpenForSubmission:!1,hash:"9261926500acb26c4ae5a29eee78f0db",slug:"prunus-recent-advances",bookSignature:"Ayzin B. Küden and Ali Küden",coverURL:"https://cdn.intechopen.com/books/images_new/10900.jpg",editedByType:"Edited by",publishedDate:"July 6th 2022",editors:[{id:"200365",title:"Prof.",name:"Ayzin B.",middleName:"B.",surname:"Küden",slug:"ayzin-b.-kuden",fullName:"Ayzin B. Küden"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"170",title:"Cardiology and Cardiovascular Medicine",slug:"cardiology-and-cardiovascular-medicine",parent:{id:"16",title:"Medicine",slug:"medicine"},numberOfBooks:129,numberOfSeries:0,numberOfAuthorsAndEditors:3253,numberOfWosCitations:1444,numberOfCrossrefCitations:962,numberOfDimensionsCitations:2205,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"170",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"10863",title:"Cardiac Rhythm Management",subtitle:"Pacing, Ablation, Devices",isOpenForSubmission:!1,hash:"a064ec49b85ebfc60585c9c3690af53a",slug:"cardiac-rhythm-management-pacing-ablation-devices",bookSignature:"Mart Min and Gabriel Cismaru",coverURL:"https://cdn.intechopen.com/books/images_new/10863.jpg",editedByType:"Edited by",editors:[{id:"62780",title:"Prof.",name:"Mart",middleName:null,surname:"Min",slug:"mart-min",fullName:"Mart Min"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10703",title:"Risk Factors for Cardiovascular Disease",subtitle:null,isOpenForSubmission:!1,hash:"ce44a740aa9c4322a02614b2033deceb",slug:"risk-factors-for-cardiovascular-disease",bookSignature:"Johnny Chahine",coverURL:"https://cdn.intechopen.com/books/images_new/10703.jpg",editedByType:"Edited by",editors:[{id:"339234",title:"Dr.",name:"Johnny",middleName:null,surname:"Chahine",slug:"johnny-chahine",fullName:"Johnny Chahine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10704",title:"Cardiac Arrhythmias",subtitle:"Translational Approach from Pathophysiology to Advanced Care",isOpenForSubmission:!1,hash:"0e5d67464d929fda6d8c83ec20c4138a",slug:"cardiac-arrhythmias-translational-approach-from-pathophysiology-to-advanced-care",bookSignature:"Endre Zima",coverURL:"https://cdn.intechopen.com/books/images_new/10704.jpg",editedByType:"Edited by",editors:[{id:"201263",title:"Dr.",name:"Endre",middleName:null,surname:"Zima",slug:"endre-zima",fullName:"Endre Zima"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10305",title:"Interventional Treatment for Structural Heart Disease",subtitle:null,isOpenForSubmission:!1,hash:"e8c71690cc70efeb0efbfee95b81f9ec",slug:"interventional-treatment-for-structural-heart-disease",bookSignature:"Takashi Murashita",coverURL:"https://cdn.intechopen.com/books/images_new/10305.jpg",editedByType:"Edited by",editors:[{id:"192448",title:"Dr.",name:"Takashi",middleName:null,surname:"Murashita",slug:"takashi-murashita",fullName:"Takashi Murashita"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10303",title:"Cardiomyopathy",subtitle:"Disease of the Heart Muscle",isOpenForSubmission:!1,hash:"3fa88fd83f8f58fb421674a123bd86ed",slug:"cardiomyopathy-disease-of-the-heart-muscle",bookSignature:"Gustav Mattsson and Peter Magnusson",coverURL:"https://cdn.intechopen.com/books/images_new/10303.jpg",editedByType:"Edited by",editors:[{id:"238220",title:"Dr.",name:"Gustav",middleName:null,surname:"Mattsson",slug:"gustav-mattsson",fullName:"Gustav Mattsson"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9581",title:"Advanced Concepts in Endocarditis",subtitle:"2021",isOpenForSubmission:!1,hash:"6f230bb91e4ccf020818f2d5b2d19910",slug:"advanced-concepts-in-endocarditis-2021",bookSignature:"Michael S. Firstenberg and Umashankar Lakshmanadoss",coverURL:"https://cdn.intechopen.com/books/images_new/9581.jpg",editedByType:"Edited by",editors:[{id:"64343",title:"Dr.",name:"Michael S.",middleName:null,surname:"Firstenberg",slug:"michael-s.-firstenberg",fullName:"Michael S. Firstenberg"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9578",title:"Cardiac Diseases",subtitle:"Novel Aspects of Cardiac Risk, Cardiorenal Pathology and Cardiac Interventions",isOpenForSubmission:!1,hash:"9a5bbee0025f348afb4f26660de011f5",slug:"cardiac-diseases-novel-aspects-of-cardiac-risk-cardiorenal-pathology-and-cardiac-interventions",bookSignature:"David C. Gaze and Aleksandar Kibel",coverURL:"https://cdn.intechopen.com/books/images_new/9578.jpg",editedByType:"Edited by",editors:[{id:"71983",title:"Dr.",name:"David C.",middleName:null,surname:"Gaze",slug:"david-c.-gaze",fullName:"David C. Gaze"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9496",title:"Management of Dyslipidemia",subtitle:null,isOpenForSubmission:!1,hash:"1d1174ff4ed8ad553c944e99add28154",slug:"management-of-dyslipidemia",bookSignature:"Wilbert S. Aronow",coverURL:"https://cdn.intechopen.com/books/images_new/9496.jpg",editedByType:"Edited by",editors:[{id:"164597",title:"Dr.",name:"Wilbert S.",middleName:null,surname:"Aronow",slug:"wilbert-s.-aronow",fullName:"Wilbert S. Aronow"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7016",title:"Cardiovascular Risk Factors in Pathology",subtitle:null,isOpenForSubmission:!1,hash:"7937d2c640c7515de372282c72ee5635",slug:"cardiovascular-risk-factors-in-pathology",bookSignature:"Alaeddin Abukabda, Maria Suciu and Minodora Andor",coverURL:"https://cdn.intechopen.com/books/images_new/7016.jpg",editedByType:"Edited by",editors:[{id:"307873",title:"Ph.D.",name:"Alaeddin",middleName:null,surname:"Abukabda",slug:"alaeddin-abukabda",fullName:"Alaeddin Abukabda"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10124",title:"Sudden Cardiac Death",subtitle:null,isOpenForSubmission:!1,hash:"ca46358f48d8781fa3df4e80e393fc8f",slug:"sudden-cardiac-death",bookSignature:"Peter Magnusson and Jo Ann LeQuang",coverURL:"https://cdn.intechopen.com/books/images_new/10124.jpg",editedByType:"Edited by",editors:[{id:"188088",title:"Dr.",name:"Peter",middleName:null,surname:"Magnusson",slug:"peter-magnusson",fullName:"Peter Magnusson"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8300",title:"Vascular Biology",subtitle:"Selection of Mechanisms and Clinical Applications",isOpenForSubmission:!1,hash:"478078d1af7d5e3c606698a33dc2550b",slug:"vascular-biology-selection-of-mechanisms-and-clinical-applications",bookSignature:"Marcelo",coverURL:"https://cdn.intechopen.com/books/images_new/8300.jpg",editedByType:"Edited by",editors:[{id:"202594",title:"Dr.",name:"Marcelo",middleName:null,surname:"González",slug:"marcelo-gonzalez",fullName:"Marcelo González"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8217",title:"Aortic Aneurysm and Aortic Dissection",subtitle:null,isOpenForSubmission:!1,hash:"cffb188ad7ddd3f31691c098dc8b9c73",slug:"aortic-aneurysm-and-aortic-dissection",bookSignature:"Jeffrey Shuhaiber",coverURL:"https://cdn.intechopen.com/books/images_new/8217.jpg",editedByType:"Edited by",editors:[{id:"22152",title:"Dr.",name:"Jeffrey",middleName:null,surname:"Shuhaiber",slug:"jeffrey-shuhaiber",fullName:"Jeffrey Shuhaiber"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:129,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"45069",doi:"10.5772/54354",title:"The Immune Response in In Situ Tissue Engineering of Aortic Heart Valves",slug:"the-immune-response-in-in-situ-tissue-engineering-of-aortic-heart-valves",totalDownloads:5228,totalCrossrefCites:17,totalDimensionsCites:37,abstract:null,book:{id:"3384",slug:"calcific-aortic-valve-disease",title:"Calcific Aortic Valve Disease",fullTitle:"Calcific Aortic Valve Disease"},signatures:"S. L. M. van Loon, A. I. P. M. Smits, A. Driessen-Mol, F. P. T. Baaijens\nand C. V. C. Bouten",authors:[{id:"159635",title:"Prof.",name:"Carlijn",middleName:"V",surname:"Bouten",slug:"carlijn-bouten",fullName:"Carlijn Bouten"},{id:"161227",title:"MSc.",name:"Saskia",middleName:null,surname:"Van Loon",slug:"saskia-van-loon",fullName:"Saskia Van Loon"},{id:"161228",title:"MSc.",name:"Anthal",middleName:null,surname:"Smits",slug:"anthal-smits",fullName:"Anthal Smits"},{id:"161229",title:"Dr.",name:"Anita",middleName:null,surname:"Driessen-Mol",slug:"anita-driessen-mol",fullName:"Anita Driessen-Mol"},{id:"161230",title:"Prof.",name:"Frank",middleName:null,surname:"Baaijens",slug:"frank-baaijens",fullName:"Frank Baaijens"}]},{id:"47808",doi:"10.5772/59375",title:"Role of Oxidized LDL in Atherosclerosis",slug:"role-of-oxidized-ldl-in-atherosclerosis",totalDownloads:5031,totalCrossrefCites:18,totalDimensionsCites:29,abstract:null,book:{id:"4477",slug:"hypercholesterolemia",title:"Hypercholesterolemia",fullTitle:"Hypercholesterolemia"},signatures:"E. Leiva, S. Wehinger, L. Guzmán and R. Orrego",authors:[{id:"153453",title:"MSc.",name:"Elba",middleName:null,surname:"Leiva",slug:"elba-leiva",fullName:"Elba Leiva"}]},{id:"53316",doi:"10.5772/66405",title:"TGF-β Activation and Signaling in Angiogenesis",slug:"tgf-activation-and-signaling-in-angiogenesis",totalDownloads:2443,totalCrossrefCites:12,totalDimensionsCites:25,abstract:"The transforming growth factor-β (TGF-β) signaling pathway regulates various cellular processes during tissue and organ development and homeostasis. Deregulation of the expression and/or functions of TGF-β ligands, receptors or their intracellular signaling components leads to multiple diseases including vascular pathologies, autoimmune disorders, fibrosis and cancer. In vascular development, physiology and disease TGF-β signaling can have angiogenic and angiostatic properties, depending on expression levels and the tissue context. The objective of this chapter is to analyze the mechanisms that contribute to the activation and signaling of TGF-β in developmental, physiological and pathological angiogenesis, with a particular emphasis on the importance of TGF-β signaling in the mammalian central nervous system (CNS).",book:{id:"5682",slug:"physiologic-and-pathologic-angiogenesis-signaling-mechanisms-and-targeted-therapy",title:"Physiologic and Pathologic Angiogenesis",fullTitle:"Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy"},signatures:"Paola A. Guerrero and Joseph H. McCarty",authors:[{id:"193482",title:"Dr.",name:"Paola",middleName:null,surname:"Guerrero",slug:"paola-guerrero",fullName:"Paola Guerrero"},{id:"195670",title:"Dr.",name:"Joseph",middleName:null,surname:"McCarty",slug:"joseph-mccarty",fullName:"Joseph McCarty"}]},{id:"44726",doi:"10.5772/52842",title:"Extracellular Matrix Organization, Structure, and Function",slug:"extracellular-matrix-organization-structure-and-function",totalDownloads:3139,totalCrossrefCites:13,totalDimensionsCites:24,abstract:null,book:{id:"3384",slug:"calcific-aortic-valve-disease",title:"Calcific Aortic Valve Disease",fullTitle:"Calcific Aortic Valve Disease"},signatures:"Dena Wiltz, C. Alexander Arevalos, Liezl R. Balaoing, Alicia A.\nBlancas, Matthew C. Sapp, Xing Zhang and K. Jane Grande-Allen",authors:[{id:"159730",title:"Ph.D. Student",name:"Dena",middleName:null,surname:"Wiltz",slug:"dena-wiltz",fullName:"Dena Wiltz"},{id:"160472",title:"Dr.",name:"Alicia",middleName:null,surname:"Blancas",slug:"alicia-blancas",fullName:"Alicia Blancas"},{id:"160474",title:"Ms.",name:"Liezl",middleName:null,surname:"Balaoing",slug:"liezl-balaoing",fullName:"Liezl Balaoing"},{id:"160476",title:"Mr.",name:"Alex",middleName:null,surname:"Arevalos",slug:"alex-arevalos",fullName:"Alex Arevalos"},{id:"160477",title:"Mr.",name:"Matthew",middleName:null,surname:"Sapp",slug:"matthew-sapp",fullName:"Matthew Sapp"},{id:"160478",title:"Dr.",name:"Xing",middleName:null,surname:"Zhang",slug:"xing-zhang",fullName:"Xing Zhang"},{id:"160479",title:"Dr.",name:"K. Jane",middleName:null,surname:"Grande-Allen",slug:"k.-jane-grande-allen",fullName:"K. Jane Grande-Allen"}]},{id:"59778",doi:"10.5772/intechopen.74768",title:"Epidemiology of Myocardial Infarction",slug:"epidemiology-of-myocardial-infarction",totalDownloads:4515,totalCrossrefCites:12,totalDimensionsCites:24,abstract:"Coronary heart disease (CHD) is the leading cause of morbidity and mortality throughout the world. The most common form of CHD is the myocardial infarction. It is responsible for over 15% of mortality each year, among the vast majority of people suffering from non-ST-segment elevation myocardial infarction (NSTEMI) than ST-segment elevation myocardial infarction (STEMI). The prevalence of myocardial infarction (MI) is higher in men in all age-specific groups than women. Although the incidence of MI is decreased in the industrialized nations partly because of improved health systems and implementation of effective public health strategies, nevertheless the rates are surging in the developing countries such as South Asia, parts of Latin America, and Eastern Europe. The modifiable risk factors represent over 90% of the risk for acute MI. The risk factors such as dyslipidemia, smoking, psychosocial stressors, diabetes mellitus, hypertension, obesity, alcohol consumption, physical inactivity, and a diet low in fruits and vegetables were strongly associated with acute MI.",book:{id:"6373",slug:"myocardial-infarction",title:"Myocardial Infarction",fullTitle:"Myocardial Infarction"},signatures:"Joshua Chadwick Jayaraj, Karapet Davatyan, S.S. Subramanian and Jemmi Priya",authors:[{id:"223196",title:"Dr.",name:"Joshua",middleName:null,surname:"Chadwick",slug:"joshua-chadwick",fullName:"Joshua Chadwick"},{id:"231054",title:"Dr.",name:"Karapet",middleName:null,surname:"Davatyan",slug:"karapet-davatyan",fullName:"Karapet Davatyan"},{id:"231055",title:"Ms.",name:"Jemmi",middleName:null,surname:"Priya",slug:"jemmi-priya",fullName:"Jemmi Priya"},{id:"244487",title:"Dr.",name:"S.S.",middleName:null,surname:"Subramanian",slug:"s.s.-subramanian",fullName:"S.S. Subramanian"}]}],mostDownloadedChaptersLast30Days:[{id:"80213",title:"Evolution of Heart Transplantation Surgical Techniques",slug:"evolution-of-heart-transplantation-surgical-techniques",totalDownloads:241,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"Organ transplantation has kindled the human imagination since the beginning of time. Prehistorically, transplantation appeared as mythological stories: from creatures with body parts from different species, the heart transplant between two Chinese soldiers by Pien Ch’iao, to the leg transplant by physician Saints Cosmas and Damian. By 19th century, the transplantation concept become possible by extensive contributions from scientists and clinicians whose works had taken generations. Although Alexis Carrel is known as the founding father of experimental organ transplantation, many legendary names had contributed to the experimental works of heart transplantation, including Guthrie, Mann, and Demikhov. The major contribution to experimental heart transplantation before the clinical era were made by a team lead by Richard Lower and Norman Shumway at Stanford University in the early 1960s. They played the vital role in developing experimental and clinical heart transplantation as it is known today. Using Shumway biatrial technique Christiaan Barnard started a new era of clinical heart transplantation, by performing the first in man human-to-human heart transplantation in 1967. The techniques of heart transplant have evolved since the first heart transplant. This chapter will summarize the techniques that have been used in clinical heart transplantation.",book:{id:"11236",slug:null,title:"Heart Transplantation - New Insights in Therapeutic Strategies",fullTitle:"Heart Transplantation - New Insights in Therapeutic Strategies"},signatures:"Samuel Jacob, Anthony N. Pham and Si M. Pham",authors:null},{id:"65757",title:"Prevalence of Dyslipidemia and Goal Attainment with Lipid-Lowering Therapy: Insights from Thai Multicenter Study and Overview of the Major Guidelines",slug:"prevalence-of-dyslipidemia-and-goal-attainment-with-lipid-lowering-therapy-insights-from-thai-multic",totalDownloads:2359,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"Background Since the release in Thailand in 2001 of the Third Guidelines by the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults or the Adult Treatment Panel (ATP III), there have been no nationwide studies on the proportion of dyslipidaemic patients who have achieved the low-density lipoprotein cholesterol (LDL-C) goals. The authors therefore aimed to estimate the percentage achievement of LDL-C goals based on the modified NCEP ATP III guidelines in intermediate- to high-risk patients. Methods The authors conducted a hospital-based, cross-sectional, epidemiological survey. Patients (1240) were selected consecutively from 50 hospitals across Thailand. Patients were included if they had been treated with statins for at least 3 months. Results Two-thirds were female, and the mean age was 61.7+69.5 years. The median duration of statin treatment was 21 months. Half (633/1240) of the patients achieved the LDL-C goal levels as defined by the NCEP guidelines (51.1%, 95% CI 48.3% to 53.8%). The very high-risk group had the lowest percentage achievement (11.6%; 95% CI 1.6% to 21.6%), compared with 54.2% (95% CI 50.9% to 57.4%) for the high-risk group and 47.0% (95% CI 41.1% to 52.8%) for the moderate-risk group. More males achieved the LDL-C goals than females (55.6% vs. 48.9%; P = 0.029). Conclusions Overall, 51.1% of the patients with cardiovascular risk, on statins treatment, achieved the NCEP ATP III LDL-C goal levels.",book:{id:"7556",slug:"dyslipidemia",title:"Dyslipidemia",fullTitle:"Dyslipidemia"},signatures:"Songkwan Silaruks, Charn Sriratanasathavorn, Petch Rawdaree, Rapeephon Kunjara-Na-Ayudhaya, Bandit Thinkhamrop and Piyamitr Sritara",authors:[{id:"256769",title:"Prof.",name:"Songkwan",middleName:null,surname:"Silaruks",slug:"songkwan-silaruks",fullName:"Songkwan Silaruks"},{id:"283455",title:"Dr.",name:"Charn",middleName:null,surname:"Sriratanasathavorn",slug:"charn-sriratanasathavorn",fullName:"Charn Sriratanasathavorn"},{id:"283456",title:"Dr.",name:"Petch",middleName:null,surname:"Rawdaree",slug:"petch-rawdaree",fullName:"Petch Rawdaree"},{id:"283457",title:"Dr.",name:"Rapeephon",middleName:null,surname:"Kunjara-Na-Ayudhaya",slug:"rapeephon-kunjara-na-ayudhaya",fullName:"Rapeephon Kunjara-Na-Ayudhaya"},{id:"283458",title:"Dr.",name:"Bandit",middleName:null,surname:"Thinkhamrop",slug:"bandit-thinkhamrop",fullName:"Bandit Thinkhamrop"},{id:"283459",title:"Prof.",name:"Piyamitr",middleName:null,surname:"Sritara",slug:"piyamitr-sritara",fullName:"Piyamitr Sritara"}]},{id:"59778",title:"Epidemiology of Myocardial Infarction",slug:"epidemiology-of-myocardial-infarction",totalDownloads:4507,totalCrossrefCites:11,totalDimensionsCites:24,abstract:"Coronary heart disease (CHD) is the leading cause of morbidity and mortality throughout the world. The most common form of CHD is the myocardial infarction. It is responsible for over 15% of mortality each year, among the vast majority of people suffering from non-ST-segment elevation myocardial infarction (NSTEMI) than ST-segment elevation myocardial infarction (STEMI). The prevalence of myocardial infarction (MI) is higher in men in all age-specific groups than women. Although the incidence of MI is decreased in the industrialized nations partly because of improved health systems and implementation of effective public health strategies, nevertheless the rates are surging in the developing countries such as South Asia, parts of Latin America, and Eastern Europe. The modifiable risk factors represent over 90% of the risk for acute MI. The risk factors such as dyslipidemia, smoking, psychosocial stressors, diabetes mellitus, hypertension, obesity, alcohol consumption, physical inactivity, and a diet low in fruits and vegetables were strongly associated with acute MI.",book:{id:"6373",slug:"myocardial-infarction",title:"Myocardial Infarction",fullTitle:"Myocardial Infarction"},signatures:"Joshua Chadwick Jayaraj, Karapet Davatyan, S.S. Subramanian and Jemmi Priya",authors:[{id:"223196",title:"Dr.",name:"Joshua",middleName:null,surname:"Chadwick",slug:"joshua-chadwick",fullName:"Joshua Chadwick"},{id:"231054",title:"Dr.",name:"Karapet",middleName:null,surname:"Davatyan",slug:"karapet-davatyan",fullName:"Karapet Davatyan"},{id:"231055",title:"Ms.",name:"Jemmi",middleName:null,surname:"Priya",slug:"jemmi-priya",fullName:"Jemmi Priya"},{id:"244487",title:"Dr.",name:"S.S.",middleName:null,surname:"Subramanian",slug:"s.s.-subramanian",fullName:"S.S. Subramanian"}]},{id:"70032",title:"Coronary Artery Bypass Grafting: Surgical Anastomosis: Tips and Tricks",slug:"coronary-artery-bypass-grafting-surgical-anastomosis-tips-and-tricks",totalDownloads:1363,totalCrossrefCites:0,totalDimensionsCites:2,abstract:"The definite feature of coronary artery disease is the focal narrowing in the vascular endothelium, and this leads to the decrease in the flow of blood to the myocardium. Atherosclerotic plaque is the main lesion. These patients can present with chest pain (angina or myocardial infarction) and need further workup noninvasively and invasively for the management. The main reasons for myocardial revascularization can be: (1) relief from symptoms of myocardial ischemia; (2) reduce the risks of future mortality; (3) to treat or prevent morbidities such as myocardial infarction, arrhythmias, or heart failure. Coronary artery bypass grafting (CABG) is the surgical technique of cardiac revascularization. In 1910, Dr. Alexis Carrel described a series of canine experiments in which he devised means to treat CAD by creating a “complementary circulation” for the diseased native coronary arteries. No clinical translation occurred at the time, but he was awarded the Nobel Prize in Medicine. Experimental refinements of coronary arterial revascularization, including the use of internal thoracic artery (ITA) grafts, were later reported by Murray and colleagues, Demikhov, and Goetz and colleagues in the 1950s and early 1960s. Dr. Rene Favaloro performed his first coronary bypass operation in May 1967 with an interposed saphenous vein graft (SVG) and shortly thereafter used aortocoronary bypasses sutured proximally to the ascending aorta. The stenosed segment is bypassed using an arterial or venous graft. Left internal thoracic artery is the most commonly used artery, and long saphenous vein is the most commonly used vein for the coronary artery grafting to reestablish the blood flow to the compromised myocardium. This can be performed with or without the help of cardiopulmonary bypass machine and also with or without arresting the heart. These techniques are called as on-pump beating or on-pump arrested and off-pump beating coronary artery bypass grafting surgery. Distal and proximal anastomoses are usually performed in an end-to-side manner, but in the case of doing sequential grafting, side-to-side anastomosis is also performed proximal to the end-to-side anastomosis. In this chapter we are going to discuss the coronary artery bypass grafting tips and tricks in details.",book:{id:"9060",slug:"the-current-perspectives-on-coronary-artery-bypass-grafting",title:"The Current Perspectives on Coronary Artery Bypass Grafting",fullTitle:"The Current Perspectives on Coronary Artery Bypass Grafting"},signatures:"Mohd. Shahbaaz Khan",authors:[{id:"278633",title:"Dr.",name:"Mohd. Shahbaaz",middleName:null,surname:"Khan",slug:"mohd.-shahbaaz-khan",fullName:"Mohd. Shahbaaz Khan"}]},{id:"53810",title:"Angiography and Endovascular Therapy for Below-the-Knee Artery Disease",slug:"angiography-and-endovascular-therapy-for-below-the-knee-artery-disease",totalDownloads:3130,totalCrossrefCites:1,totalDimensionsCites:1,abstract:"Critical limb ischemia (CLI) is growing in global prevalence and is associated with high rates of limb loss and mortality. “Endovascular-first” approach is considered to be the current standard care for symptomatic infrainguinal atherosclerotic disease. Given the facts that many CLI patients have severe comorbidities and endovascular-first approach is a common practice and may reduce the magnitude of the surgical trauma and systemic complications. In this chapter, updated angiographic approach for below-the-knee disease is described with endovascular technique.",book:{id:"5596",slug:"angiography-and-endovascular-therapy-for-peripheral-artery-disease",title:"Angiography and Endovascular Therapy for Peripheral Artery Disease",fullTitle:"Angiography and Endovascular Therapy for Peripheral Artery Disease"},signatures:"Akihiro Higashimori",authors:[{id:"195500",title:"Dr.",name:"Akihiro",middleName:null,surname:"Higashimori",slug:"akihiro-higashimori",fullName:"Akihiro Higashimori"}]}],onlineFirstChaptersFilter:{topicId:"170",limit:6,offset:0},onlineFirstChaptersCollection:[{id:"82507",title:"Use of Computed Tomography in the Assessment of Severity of Aortic Valve Stenosis",slug:"use-of-computed-tomography-in-the-assessment-of-severity-of-aortic-valve-stenosis",totalDownloads:2,totalDimensionsCites:0,doi:"10.5772/intechopen.105644",abstract:"The workhorse in the diagnosis of aortic stenosis (AS) has been transthoracic echocardiography (TTE) with clear-cut validated threshold values for grading it mild, moderate, or severe. However, up to one-third of patients may present with discordant findings on echo sonogram and may need further evaluation with other imaging modalities such as computed tomography (CT). CT is useful in determining aortic valve area (AVA) by planimetry and outperforms TTE in identifying severe AS in bicuspid aortic valve (BAV), but it is not routinely ordered for those purposes. It has been widely used in helping, determining, and grading the severity of AS by calculating aortic valve calcium (AVC) load with a scoring system. AVC scores of 2000 AU or more for men and 1300 AU for women are highly indicative of severe AS and have been associated with the poor outcomes. AVC score will underestimate AS in a minority of circumstances where the process is driven more by fibrosis than calcification. CT use is limited by its recent adoption into medical practice and, therefore, is still not universally available in every center. It requires additional training for providers and low-dose radiation exposure may be a concern for some patients.",book:{id:"11221",title:"Aortic Stenosis - Recent Advances, New Perspectives and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11221.jpg"},signatures:"David Weininger Cohen and Wilbert S. Aronow"},{id:"82249",title:"Perspective Chapter: Evolution of Techniques to Assess Vascular Impedance in Patients with Aortic Stenosis",slug:"perspective-chapter-evolution-of-techniques-to-assess-vascular-impedance-in-patients-with-aortic-ste",totalDownloads:9,totalDimensionsCites:0,doi:"10.5772/intechopen.104795",abstract:"Aortic stenosis (AS) once was conceptualized as a mechanical problem with a fixed left ventricular (LV) afterload because of an obstructive valve. With time, there has been growing recognition that AS functions more like a series circuit, with important contributions from the ventricle through to the vasculature. Emerging evidence suggests that higher blood pressure and increased arterial stiffness, synonymous with vascular aging, increases global LV afterload in patients with AS. This in turn, has adverse consequences on quality-of-life measures and survival. Although traditional methods have emphasized measurement of the transvalvular pressure gradient, focusing on valvular hemodynamics alone may be inadequate. By definition, total vascular load of the human circulation includes both steady and pulsatile components. Steady load is best represented by the systemic vascular resistance whereas pulsatile load occurs because of wave reflections and vascular stiffness, and is often referred to as the valvulo-arterial impedance. In the following Review, we evaluate existing and upcoming methods to assess vascular load in patients with AS in order to better understand the effects of vascular aging on this insidious disease process.",book:{id:"11221",title:"Aortic Stenosis - Recent Advances, New Perspectives and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11221.jpg"},signatures:"Sara L. Hungerford, Dhruv Nayya, Peter S. Hansen, Ravinay Bhindi and Christopher Choong"},{id:"81437",title:"Pediatric Heart Transplantation",slug:"pediatric-heart-transplantation",totalDownloads:17,totalDimensionsCites:0,doi:"10.5772/intechopen.104518",abstract:"Despite advances in medical management, patients submitted for heart transplantation procedures still are at risk to development of complications. This chapter will discuss some specific topics of pediatric heart transplantation, focusing on perioperative care: (i) recipient management, (ii) donor evaluation, (iii) immunosuppression, (iv) early postoperative management, (v) complications, and (vi) conclusions.",book:{id:"11236",title:"Heart Transplantation - New Insights in Therapeutic Strategies",coverURL:"https://cdn.intechopen.com/books/images_new/11236.jpg"},signatures:"Estela Azeka"},{id:"81451",title:"Donor Assessment and Management for Heart Transplantation",slug:"donor-assessment-and-management-for-heart-transplantation",totalDownloads:20,totalDimensionsCites:0,doi:"10.5772/intechopen.104504",abstract:"For many years, heart transplantation has been an established procedure for patients with end-stage heart failure using the so-called “Standard Criteria” for an optimal heart donor. However, annually listed patients for heart transplantation greatly increased worldwide, and the use of extended criteria donor hearts has been utilized as many as possible in many countries. In this chapter, firstly, pathophysiology of brain death is explained. Secondly, donor assessment and issues of extended criteria donors are introduced. Then, donor management to maximize the heart graft availability, and the Japanese donor assessment and evaluation system and its outcome are reviewed.",book:{id:"11236",title:"Heart Transplantation - New Insights in Therapeutic Strategies",coverURL:"https://cdn.intechopen.com/books/images_new/11236.jpg"},signatures:"Norihide Fukushima"},{id:"80955",title:"Perspective Chapter: Moderate Aortic Stenosis and Heart Failure With Reduced Ejection Fraction; Early Replacement or Conservative Treatment?",slug:"perspective-chapter-moderate-aortic-stenosis-and-heart-failure-with-reduced-ejection-fraction-early-",totalDownloads:17,totalDimensionsCites:0,doi:"10.5772/intechopen.103923",abstract:"Aortic stenosis (AS) is the most common valve lesion among the continuously aging population with serious effect on the left ventricular ejection fraction (LVEF). If left untreated, it is associated with serious complications such as heart failure (HF), pulmonary hypertension, thromboembolic events, and even sudden death. Early diagnosis and treatment is of outmost importance to avoid the above complications but also to maintain the patient’s normal heart function. Echocardiography is the key examination that assesses the severity of the stenosis, valve calcification, left ventricular (LV) function, and wall thickness. Also new imaging methods such as cardiac computed tomography (CT) and cardiac magnetic resonance imaging (MRI) help in assessing the severity of aortic valve stenosis when echocardiography has limitations. Based on the categorization of the severity of the stenosis, its treatment is determined. Although things are clear in cases of asymptomatic disease and severe stenosis, this is not the case in moderate disease. Experts and clinical trials do not define clearly which cases can be treated conservatively and which need surgical or transcatheter intervention. The purpose of this article is to gather all the latest data on the treatment of moderate aortic stenosis, especially in patients with heart failure and low ejection fraction.",book:{id:"11221",title:"Aortic Stenosis - Recent Advances, New Perspectives and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11221.jpg"},signatures:"Asterios Karakanas, Theodoros Michailidis, Christos Gogos, Dimitrios Patoulias, Georgia Nazou and Nikolaos Schizas"},{id:"81077",title:"Perspective Chapter: Valve-in-Valve Transcatheter Aortic Valve Replacement (ViV) for Failed Bioprosthetic Valves",slug:"perspective-chapter-valve-in-valve-transcatheter-aortic-valve-replacement-viv-for-failed-bioprosthet",totalDownloads:20,totalDimensionsCites:0,doi:"10.5772/intechopen.103098",abstract:"Aortic valve disease remains the second most common valvular heart disease worldwide. Surgical aortic valve replacement (SAVR) with mechanical or bioprosthetic valves and transcatheter aortic valve replacement (TAVR) with bioprosthetic valves are both approved therapies for patients with severe aortic stenosis (AS) across all surgical risk categories. On the other hand, SAVR remains the mainstay of treatment for severe aortic regurgitation (AR) with TAVR reserved for selected patients at prohibitive surgical risk. Both surgical and transcatheter bioprosthetic valves are prone to bioprosthetic valve failure (BVF) due to various etiologies, and can lead to restenosis, regurgitation, or a combination of both. BVF can now be addressed by repeat valve replacement whether surgical or valve-in-valve TAVR (ViV). ViV is a desirable option for elderly patients at high surgical risk and requires meticulous planning with pre-operative CT imaging to optimize outcomes and minimize complications.",book:{id:"11221",title:"Aortic Stenosis - Recent Advances, New Perspectives and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11221.jpg"},signatures:"Aravdeep Jhand, Vinayak Bapat, Thomas Porter and Poonam Velagapudi"}],onlineFirstChaptersTotal:21},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:104,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:32,numberOfPublishedChapters:320,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:141,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:133,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:113,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:6,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:17,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"11",title:"Biochemistry",doi:"10.5772/intechopen.72877",issn:"2632-0983",scope:"Biochemistry, the study of chemical transformations occurring within living organisms, impacts all areas of life sciences, from molecular crystallography and genetics to ecology, medicine, and population biology. Biochemistry examines macromolecules - proteins, nucleic acids, carbohydrates, and lipids – and their building blocks, structures, functions, and interactions. Much of biochemistry is devoted to enzymes, proteins that catalyze chemical reactions, enzyme structures, mechanisms of action and their roles within cells. Biochemistry also studies small signaling molecules, coenzymes, inhibitors, vitamins, and hormones, which play roles in life processes. Biochemical experimentation, besides coopting classical chemistry methods, e.g., chromatography, adopted new techniques, e.g., X-ray diffraction, electron microscopy, NMR, radioisotopes, and developed sophisticated microbial genetic tools, e.g., auxotroph mutants and their revertants, fermentation, etc. More recently, biochemistry embraced the ‘big data’ omics systems. Initial biochemical studies have been exclusively analytic: dissecting, purifying, and examining individual components of a biological system; in the apt words of Efraim Racker (1913 –1991), “Don’t waste clean thinking on dirty enzymes.” Today, however, biochemistry is becoming more agglomerative and comprehensive, setting out to integrate and describe entirely particular biological systems. The ‘big data’ metabolomics can define the complement of small molecules, e.g., in a soil or biofilm sample; proteomics can distinguish all the comprising proteins, e.g., serum; metagenomics can identify all the genes in a complex environment, e.g., the bovine rumen. This Biochemistry Series will address the current research on biomolecules and the emerging trends with great promise.",coverUrl:"https://cdn.intechopen.com/series/covers/11.jpg",latestPublicationDate:"July 5th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:32,editor:{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"14",title:"Cell and Molecular Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/14.jpg",isOpenForSubmission:!0,editor:{id:"165627",title:"Dr.",name:"Rosa María",middleName:null,surname:"Martínez-Espinosa",slug:"rosa-maria-martinez-espinosa",fullName:"Rosa María Martínez-Espinosa",profilePictureURL:"https://mts.intechopen.com/storage/users/165627/images/system/165627.jpeg",biography:"Dr. Rosa María Martínez-Espinosa has been a Spanish Full Professor since 2020 (Biochemistry and Molecular Biology) and is currently Vice-President of International Relations and Cooperation development and leader of the research group 'Applied Biochemistry” (University of Alicante, Spain). Other positions she has held at the university include Vice-Dean of Master Programs, Vice-Dean of the Degree in Biology and Vice-Dean for Mobility and Enterprise and Engagement at the Faculty of Science (University of Alicante). She received her Bachelor in Biology in 1998 (University of Alicante) and her PhD in 2003 (Biochemistry, University of Alicante). She undertook post-doctoral research at the University of East Anglia (Norwich, U.K. 2004-2005; 2007-2008).\nHer multidisciplinary research focuses on investigating archaea and their potential applications in biotechnology. She has an H-index of 21. She has authored one patent and has published more than 70 indexed papers and around 60 book chapters.\nShe has contributed to more than 150 national and international meetings during the last 15 years. Her research interests include archaea metabolism, enzymes purification and characterization, gene regulation, carotenoids and bioplastics production, antioxidant\ncompounds, waste water treatments, and brines bioremediation.\nRosa María’s other roles include editorial board member for several journals related\nto biochemistry, reviewer for more than 60 journals (biochemistry, molecular biology, biotechnology, chemistry and microbiology) and president of several organizing committees in international meetings related to the N-cycle or respiratory processes.",institutionString:null,institution:{name:"University of Alicante",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null},{id:"15",title:"Chemical Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/15.jpg",isOpenForSubmission:!0,editor:{id:"441442",title:"Dr.",name:"Şükrü",middleName:null,surname:"Beydemir",slug:"sukru-beydemir",fullName:"Şükrü Beydemir",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003GsUoIQAV/Profile_Picture_1634557147521",biography:"Dr. Şükrü Beydemir obtained a BSc in Chemistry in 1995 from Yüzüncü Yıl University, MSc in Biochemistry in 1998, and PhD in Biochemistry in 2002 from Atatürk University, Turkey. He performed post-doctoral studies at Max-Planck Institute, Germany, and University of Florence, Italy in addition to making several scientific visits abroad. He currently works as a Full Professor of Biochemistry in the Faculty of Pharmacy, Anadolu University, Turkey. Dr. Beydemir has published over a hundred scientific papers spanning protein biochemistry, enzymology and medicinal chemistry, reviews, book chapters and presented several conferences to scientists worldwide. He has received numerous publication awards from various international scientific councils. He serves in the Editorial Board of several international journals. Dr. Beydemir is also Rector of Bilecik Şeyh Edebali University, Turkey.",institutionString:null,institution:{name:"Anadolu University",institutionURL:null,country:{name:"Turkey"}}},editorTwo:{id:"13652",title:"Prof.",name:"Deniz",middleName:null,surname:"Ekinci",slug:"deniz-ekinci",fullName:"Deniz Ekinci",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYLT1QAO/Profile_Picture_1634557223079",biography:"Dr. Deniz Ekinci obtained a BSc in Chemistry in 2004, MSc in Biochemistry in 2006, and PhD in Biochemistry in 2009 from Atatürk University, Turkey. He studied at Stetson University, USA, in 2007-2008 and at the Max Planck Institute of Molecular Cell Biology and Genetics, Germany, in 2009-2010. Dr. Ekinci currently works as a Full Professor of Biochemistry in the Faculty of Agriculture and is the Head of the Enzyme and Microbial Biotechnology Division, Ondokuz Mayıs University, Turkey. He is a member of the Turkish Biochemical Society, American Chemical Society, and German Genetics society. Dr. Ekinci published around ninety scientific papers, reviews and book chapters, and presented several conferences to scientists. He has received numerous publication awards from several scientific councils. Dr. Ekinci serves as the Editor in Chief of four international books and is involved in the Editorial Board of several international journals.",institutionString:null,institution:{name:"Ondokuz Mayıs University",institutionURL:null,country:{name:"Turkey"}}},editorThree:null},{id:"17",title:"Metabolism",coverUrl:"https://cdn.intechopen.com/series_topics/covers/17.jpg",isOpenForSubmission:!0,editor:{id:"138626",title:"Dr.",name:"Yannis",middleName:null,surname:"Karamanos",slug:"yannis-karamanos",fullName:"Yannis Karamanos",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6Jv2QAE/Profile_Picture_1629356660984",biography:"Yannis Karamanos, born in Greece in 1953, completed his pre-graduate studies at the Université Pierre et Marie Curie, Paris, then his Masters and Doctoral degree at the Université de Lille (1983). He was associate professor at the University of Limoges (1987) before becoming full professor of biochemistry at the Université d’Artois (1996). He worked on the structure-function relationships of glycoconjugates and his main project was the investigations on the biological roles of the de-N-glycosylation enzymes (Endo-N-acetyl-β-D-glucosaminidase and peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidase). From 2002 he contributes to the understanding of the Blood-brain barrier functioning using proteomics approaches. He has published more than 70 papers. His teaching areas are energy metabolism and regulation, integration and organ specialization and metabolic adaptation.",institutionString:null,institution:{name:"Artois University",institutionURL:null,country:{name:"France"}}},editorTwo:null,editorThree:null},{id:"18",title:"Proteomics",coverUrl:"https://cdn.intechopen.com/series_topics/covers/18.jpg",isOpenForSubmission:!0,editor:{id:"200689",title:"Prof.",name:"Paolo",middleName:null,surname:"Iadarola",slug:"paolo-iadarola",fullName:"Paolo Iadarola",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSCl8QAG/Profile_Picture_1623568118342",biography:"Paolo Iadarola graduated with a degree in Chemistry from the University of Pavia (Italy) in July 1972. He then worked as an Assistant Professor at the Faculty of Science of the same University until 1984. In 1985, Prof. Iadarola became Associate Professor at the Department of Biology and Biotechnologies of the University of Pavia and retired in October 2017. Since then, he has been working as an Adjunct Professor in the same Department at the University of Pavia. His research activity during the first years was primarily focused on the purification and structural characterization of enzymes from animal and plant sources. During this period, Prof. Iadarola familiarized himself with the conventional techniques used in column chromatography, spectrophotometry, manual Edman degradation, and electrophoresis). Since 1995, he has been working on: i) the determination in biological fluids (serum, urine, bronchoalveolar lavage, sputum) of proteolytic activities involved in the degradation processes of connective tissue matrix, and ii) on the identification of biological markers of lung diseases. In this context, he has developed and validated new methodologies (e.g., Capillary Electrophoresis coupled to Laser-Induced Fluorescence, CE-LIF) whose application enabled him to determine both the amounts of biochemical markers (Desmosines) in urine/serum of patients affected by Chronic Obstructive Pulmonary Disease (COPD) and the activity of proteolytic enzymes (Human Neutrophil Elastase, Cathepsin G, Pseudomonas aeruginosa elastase) in sputa of these patients. More recently, Prof. Iadarola was involved in developing techniques such as two-dimensional electrophoresis coupled to liquid chromatography/mass spectrometry (2DE-LC/MS) for the proteomic analysis of biological fluids aimed at the identification of potential biomarkers of different lung diseases. He is the author of about 150 publications (According to Scopus: H-Index: 23; Total citations: 1568- According to WOS: H-Index: 20; Total Citations: 1296) of peer-reviewed international journals. He is a Consultant Reviewer for several journals, including the Journal of Chromatography A, Journal of Chromatography B, Plos ONE, Proteomes, International Journal of Molecular Science, Biotech, Electrophoresis, and others. He is also Associate Editor of Biotech.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorTwo:{id:"201414",title:"Dr.",name:"Simona",middleName:null,surname:"Viglio",slug:"simona-viglio",fullName:"Simona Viglio",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRKDHQA4/Profile_Picture_1630402531487",biography:"Simona Viglio is an Associate Professor of Biochemistry at the Department of Molecular Medicine at the University of Pavia. She has been working since 1995 on the determination of proteolytic enzymes involved in the degradation process of connective tissue matrix and on the identification of biological markers of lung diseases. She gained considerable experience in developing and validating new methodologies whose applications allowed her to determine both the amount of biomarkers (Desmosine and Isodesmosine) in the urine of patients affected by COPD, and the activity of proteolytic enzymes (HNE, Cathepsin G, Pseudomonas aeruginosa elastase) in the sputa of these patients. Simona Viglio was also involved in research dealing with the supplementation of amino acids in patients with brain injury and chronic heart failure. She is presently engaged in the development of 2-DE and LC-MS techniques for the study of proteomics in biological fluids. The aim of this research is the identification of potential biomarkers of lung diseases. She is an author of about 90 publications (According to Scopus: H-Index: 23; According to WOS: H-Index: 20) on peer-reviewed journals, a member of the “Società Italiana di Biochimica e Biologia Molecolare,“ and a Consultant Reviewer for International Journal of Molecular Science, Journal of Chromatography A, COPD, Plos ONE and Nutritional Neuroscience.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorThree:null}]},overviewPageOFChapters:{paginationCount:38,paginationItems:[{id:"82531",title:"Abnormal Iron Metabolism and Its Effect on Dentistry",doi:"10.5772/intechopen.104502",signatures:"Chinmayee Dahihandekar and Sweta Kale Pisulkar",slug:"abnormal-iron-metabolism-and-its-effect-on-dentistry",totalDownloads:1,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Iron Metabolism - Iron a Double‐Edged Sword",coverURL:"https://cdn.intechopen.com/books/images_new/10842.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"82291",title:"The Role of Oxidative Stress in the Onset and Development of Age-Related Macular Degeneration",doi:"10.5772/intechopen.105599",signatures:"Emina Čolak, Lepša Žorić, Miloš Mirković, Jana Mirković, Ilija Dragojević, Dijana Mirić, Bojana Kisić and Ljubinka Nikolić",slug:"the-role-of-oxidative-stress-in-the-onset-and-development-of-age-related-macular-degeneration",totalDownloads:1,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Importance of Oxidative Stress and Antioxidant System in Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/11671.jpg",subseries:{id:"15",title:"Chemical Biology"}}},{id:"82195",title:"Endoplasmic Reticulum: A Hub in Lipid Homeostasis",doi:"10.5772/intechopen.105450",signatures:"Raúl Ventura and María Isabel Hernández-Alvarez",slug:"endoplasmic-reticulum-a-hub-in-lipid-homeostasis",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Updates on Endoplasmic Reticulum",coverURL:"https://cdn.intechopen.com/books/images_new/11674.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"82409",title:"Purinergic Signaling in Covid-19 Disease",doi:"10.5772/intechopen.105008",signatures:"Hailian Shen",slug:"purinergic-signaling-in-covid-19-disease",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}}]},overviewPagePublishedBooks:{paginationCount:32,paginationItems:[{type:"book",id:"7006",title:"Biochemistry and Health Benefits of Fatty Acids",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7006.jpg",slug:"biochemistry-and-health-benefits-of-fatty-acids",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Viduranga Waisundara",hash:"c93a00abd68b5eba67e5e719f67fd20b",volumeInSeries:1,fullTitle:"Biochemistry and Health Benefits of Fatty Acids",editors:[{id:"194281",title:"Dr.",name:"Viduranga Y.",middleName:null,surname:"Waisundara",slug:"viduranga-y.-waisundara",fullName:"Viduranga Y. Waisundara",profilePictureURL:"https://mts.intechopen.com/storage/users/194281/images/system/194281.jpg",biography:"Dr. Viduranga Waisundara obtained her Ph.D. in Food Science\nand Technology from the Department of Chemistry, National\nUniversity of Singapore, in 2010. She was a lecturer at Temasek Polytechnic, Singapore from July 2009 to March 2013.\nShe relocated to her motherland of Sri Lanka and spearheaded the Functional Food Product Development Project at the\nNational Institute of Fundamental Studies from April 2013 to\nOctober 2016. She was a senior lecturer on a temporary basis at the Department of\nFood Technology, Faculty of Technology, Rajarata University of Sri Lanka. She is\ncurrently Deputy Principal of the Australian College of Business and Technology –\nKandy Campus, Sri Lanka. She is also the Global Harmonization Initiative (GHI)",institutionString:"Australian College of Business & Technology",institution:{name:"Kobe College",institutionURL:null,country:{name:"Japan"}}}]},{type:"book",id:"6820",title:"Keratin",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6820.jpg",slug:"keratin",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Miroslav Blumenberg",hash:"6def75cd4b6b5324a02b6dc0359896d0",volumeInSeries:2,fullTitle:"Keratin",editors:[{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}}]},{type:"book",id:"7978",title:"Vitamin A",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7978.jpg",slug:"vitamin-a",publishedDate:"May 15th 2019",editedByType:"Edited by",bookSignature:"Leila Queiroz Zepka, Veridiana Vera de Rosso and Eduardo Jacob-Lopes",hash:"dad04a658ab9e3d851d23705980a688b",volumeInSeries:3,fullTitle:"Vitamin A",editors:[{id:"261969",title:"Dr.",name:"Leila",middleName:null,surname:"Queiroz Zepka",slug:"leila-queiroz-zepka",fullName:"Leila Queiroz Zepka",profilePictureURL:"https://mts.intechopen.com/storage/users/261969/images/system/261969.png",biography:"Prof. Dr. Leila Queiroz Zepka is currently an associate professor in the Department of Food Technology and Science, Federal University of Santa Maria, Brazil. She has more than fifteen years of teaching and research experience. She has published more than 550 scientific publications/communications, including 15 books, 50 book chapters, 100 original research papers, 380 research communications in national and international conferences, and 12 patents. She is a member of the editorial board of five journals and acts as a reviewer for several national and international journals. Her research interests include microalgal biotechnology with an emphasis on microalgae-based products.",institutionString:"Universidade Federal de Santa Maria",institution:{name:"Universidade Federal de Santa Maria",institutionURL:null,country:{name:"Brazil"}}}]},{type:"book",id:"7953",title:"Bioluminescence",subtitle:"Analytical Applications and Basic Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7953.jpg",slug:"bioluminescence-analytical-applications-and-basic-biology",publishedDate:"September 25th 2019",editedByType:"Edited by",bookSignature:"Hirobumi Suzuki",hash:"3a8efa00b71abea11bf01973dc589979",volumeInSeries:4,fullTitle:"Bioluminescence - Analytical Applications and Basic Biology",editors:[{id:"185746",title:"Dr.",name:"Hirobumi",middleName:null,surname:"Suzuki",slug:"hirobumi-suzuki",fullName:"Hirobumi Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/185746/images/system/185746.png",biography:"Dr. Hirobumi Suzuki received his Ph.D. in 1997 from Tokyo Metropolitan University, Japan, where he studied firefly phylogeny and the evolution of mating systems. He is especially interested in the genetic differentiation pattern and speciation process that correlate to the flashing pattern and mating behavior of some fireflies in Japan. He then worked for Olympus Corporation, a Japanese manufacturer of optics and imaging products, where he was involved in the development of luminescence technology and produced a bioluminescence microscope that is currently being used for gene expression analysis in chronobiology, neurobiology, and developmental biology. Dr. Suzuki currently serves as a visiting researcher at Kogakuin University, Japan, and also a vice president of the Japan Firefly Society.",institutionString:"Kogakuin University",institution:null}]}]},openForSubmissionBooks:{paginationCount:4,paginationItems:[{id:"11674",title:"Updates on Endoplasmic Reticulum",coverURL:"https://cdn.intechopen.com/books/images_new/11674.jpg",hash:"5d7d49bd80f53dad3761f78de4a862c6",secondStepPassed:!0,currentStepOfPublishingProcess:4,submissionDeadline:"May 6th 2022",isOpenForSubmission:!0,editors:[{id:"238047",title:"Dr.",name:"Gaia",surname:"Favero",slug:"gaia-favero",fullName:"Gaia Favero"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11670",title:"Chitin-Chitosan - Isolation, Properties, and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11670.jpg",hash:"69f009be08998711eecfb200adc7deca",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"May 26th 2022",isOpenForSubmission:!0,editors:[{id:"176093",title:"Dr.",name:"Brajesh",surname:"Kumar",slug:"brajesh-kumar",fullName:"Brajesh Kumar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11673",title:"Stem Cell Research",coverURL:"https://cdn.intechopen.com/books/images_new/11673.jpg",hash:"13092df328080c762dd9157be18ca38c",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"July 13th 2022",isOpenForSubmission:!0,editors:[{id:"203598",title:"Ph.D.",name:"Diana",surname:"Kitala",slug:"diana-kitala",fullName:"Diana Kitala"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"12215",title:"Cell Death and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/12215.jpg",hash:"dfd456a29478fccf4ebd3294137eb1e3",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"July 29th 2022",isOpenForSubmission:!0,editors:[{id:"59529",title:"Dr.",name:"Ke",surname:"Xu",slug:"ke-xu",fullName:"Ke Xu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:17,paginationItems:[{id:"82387",title:"Kept Promises? The Evolution of the EU Financial Contribution to Climate Change",doi:"10.5772/intechopen.105541",signatures:"Cecilia Camporeale, Roberto Del Ciello and Mario Jorizzo",slug:"kept-promises-the-evolution-of-the-eu-financial-contribution-to-climate-change",totalDownloads:2,totalCrossrefCites:null,totalDimensionsCites:0,authors:[{name:"Mario",surname:"Jorizzo"},{name:"Cecilia",surname:"Camporeale"},{name:"ROBERTO",surname:"DEL CIELLO"}],book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"82524",title:"Italy’s Small Exporting Companies: Globalization and Sustainability Issues",doi:"10.5772/intechopen.105542",signatures:"Roberta Pace and Francesca Mandanici",slug:"italy-s-small-exporting-companies-globalization-and-sustainability-issues",totalDownloads:0,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"82427",title:"Our Globalization Era among Success, Obstacles and Doubts",doi:"10.5772/intechopen.105545",signatures:"Arnaldo Canziani, Annalisa Baldissera and Ahmad Kahwaji",slug:"our-globalization-era-among-success-obstacles-and-doubts",totalDownloads:15,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"82248",title:"Sustainability and Excellence: Pillars for Business Survival",doi:"10.5772/intechopen.105420",signatures:"Irina Severin, Maria Cristina Dijmarescu and Mihai Caramihai",slug:"sustainability-and-excellence-pillars-for-business-survival",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"82124",title:"Assessment of Diversity, Growth Characteristics and Aboveground Biomass of Tree Species in Selected Urban Green Areas of Osogbo, Osun State",doi:"10.5772/intechopen.104982",signatures:"Omolara Aremu, Olusola O. Adetoro and Olusegun Awotoye",slug:"assessment-of-diversity-growth-characteristics-and-aboveground-biomass-of-tree-species-in-selected-u",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Forest Degradation Under Global Change",coverURL:"https://cdn.intechopen.com/books/images_new/11457.jpg",subseries:{id:"94",title:"Climate Change and Environmental Sustainability"}}},{id:"81975",title:"Self-Sustained Communities: Food Security in Times of Crisis",doi:"10.5772/intechopen.104425",signatures:"Kriengsak Chareonwongsak",slug:"self-sustained-communities-food-security-in-times-of-crisis",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81920",title:"Rethinking an Approach for Sustainable Globalization",doi:"10.5772/intechopen.105141",signatures:"Parakram Pyakurel",slug:"rethinking-an-approach-for-sustainable-globalization",totalDownloads:22,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81297",title:"Legumes Cropping and Nitrogen Fixation under Mediterranean Climate: The Case of Montado/Dehesa System",doi:"10.5772/intechopen.104473",signatures:"Fernando Teixeira",slug:"legumes-cropping-and-nitrogen-fixation-under-mediterranean-climate-the-case-of-montado-dehesa-system",totalDownloads:24,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81493",title:"Rust Disease Classification Using Deep Learning Based Algorithm: The Case of Wheat",doi:"10.5772/intechopen.104426",signatures:"Shivani Sood, Harjeet Singh and Suruchi Jindal",slug:"rust-disease-classification-using-deep-learning-based-algorithm-the-case-of-wheat",totalDownloads:80,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81428",title:"Observatory of Sustainable Development in Postgraduate Study Programs in Baja California",doi:"10.5772/intechopen.104641",signatures:"Rodolfo Martinez-Gutierrez, Maria Marcela Solis-Quinteros, Maria Esther Ibarra-Estrada and Angel Ernesto Jimenez-Bernardino",slug:"observatory-of-sustainable-development-in-postgraduate-study-programs-in-baja-california",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}}]},subseriesFiltersForOFChapters:[{caption:"Climate Change and Environmental Sustainability",value:94,count:1,group:"subseries"},{caption:"Sustainable Economy and Fair Society",value:91,count:16,group:"subseries"}],publishedBooks:{paginationCount:1,paginationItems:[{type:"book",id:"11392",title:"Leadership in a Changing World",subtitle:"A Multidimensional Perspective",coverURL:"https://cdn.intechopen.com/books/images_new/11392.jpg",slug:"leadership-in-a-changing-world-a-multidimensional-perspective",publishedDate:"May 11th 2022",editedByType:"Edited by",bookSignature:"Muhammad Mohiuddin, Bilal Khalid, Md. Samim Al Azad and Slimane Ed-dafali",hash:"86a6d33cf601587e591064ce92effc02",volumeInSeries:1,fullTitle:"Leadership in a Changing World - A Multidimensional Perspective",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000038UqSfQAK/Profile_Picture_2022-05-13T10:39:03.jpg",institutionString:"Université Laval",institution:{name:"Université Laval",institutionURL:null,country:{name:"Canada"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Business and Management",value:86,count:1}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:1}],authors:{paginationCount:25,paginationItems:[{id:"429683",title:"Dr.",name:"Bilal",middleName:null,surname:"Khalid",slug:"bilal-khalid",fullName:"Bilal Khalid",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/429683/images/system/429683.png",biography:"Dr. Bilal Khalid received a Ph.D. in Industrial Business Administration from KMITL Business School, Bangkok, in 2021, and a master’s in International Business Management from Stamford International University, Bangkok, in 2017. Dr. Khalid\\'s research interests include leadership and negotiations, digital transformations, gamification, eLearning, blockchain, Big Data, and management of information technology. Dr. Bilal Khalid also serves as an academic editor at Education Research International and a reviewer for international journals.",institutionString:"KMITL Business School",institution:{name:"King Mongkut's Institute of Technology Ladkrabang",country:{name:"Thailand"}}},{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000038UqSfQAK/Profile_Picture_2022-05-13T10:39:03.jpg",biography:"Dr. Muhammad Mohiuddin is an Associate Professor of International Business at Laval University, Canada. He has taught at Thompson Rivers University, Canada; University of Paris-Est, France; Osnabruck University of Applied Science, Germany; and Shanghai Institute of Technology and Tianjin University of Technology, China. He has published research in Research Policy, Applied Economics, Review of Economic Philosophy, Strategic Change, International Journal of Logistics, Sustainability, Journal of Environmental Management, Journal of Global Information Management, Journal of Cleaner Production, M@N@GEMENT, and more. He is a member of CEDIMES Institut (France), Academy of International Business (AIB), Strategic Management Society (SMS), Academy of Management (AOM), Administrative Science Association of Canada (ASAC), and Canadian council of small business and entrepreneurship (CCSBE). He is currently the director of the Research Group on Contemporary Asia (GERAC) at Laval University. He is also co-managing editor of Transnational Corporations Review and a guest editor for Electronic Commerce Research and Journal of Internet Technology.",institutionString:"Université Laval",institution:{name:"Université Laval",country:{name:"Canada"}}},{id:"189147",title:"Dr.",name:"Hailan",middleName:null,surname:"Salamun",slug:"hailan-salamun",fullName:"Hailan Salamun",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/189147/images/19274_n.jpeg",biography:"Hailan Salamun, (Dr.) was born in Selangor, Malaysia and graduated from Tunku Ampuan Jamaah Religious High School at Shah Alam. Obtained a degree from the International Islamic University (UIA), Gombak in the field of Islamic Revealed Knowledge and Heritage. Next, I furthered my studies to the professional level to obtain a Diploma in Education at UIA. After serving for several years in school, I furthered my studies to the Master of Dakwah and Leadership at Universiti Kebangsaan Malaysia (UKM), Bangi. I graduated with a Doctor of Philosophy in Principalship Leadership from the University of Malaya (UM) in 2010. I am currently a senior lecturer in the Department of Nationalism and Civilization, Center for Basic and Continuing Education, Universiti Malaysia Terengganu. Prior to that, I had served in several educational institutions such as schools, the Institute of Teacher Education (IPG), and also the University of Malaya. I am also actively involved in paper presentation, writing and publishing. My research interests are focused on leadership, education, society and Islamic civilization. This area of research requires a detailed understanding of Islamic studies and research studies in leadership. Another research interest that I have explored recently is the politics of the Malay community and also the leadership of the mosque.",institutionString:null,institution:{name:"Universiti Malaysia Terengganu",country:{name:"Malaysia"}}},{id:"442081",title:"Dr.",name:"Audrey",middleName:null,surname:"Addy",slug:"audrey-addy",fullName:"Audrey Addy",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Kwame Nkrumah University of Science and Technology",country:{name:"Ghana"}}},{id:"442083",title:"Dr.",name:"James",middleName:null,surname:"Addy",slug:"james-addy",fullName:"James Addy",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Ghana Health Service",country:{name:"Ghana"}}},{id:"437993",title:"Mr.",name:"Job",middleName:null,surname:"Jackson",slug:"job-jackson",fullName:"Job Jackson",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Management College of Southern Africa",country:{name:"South Africa"}}},{id:"437991",title:"Prof.",name:"Muhammad",middleName:null,surname:"Hoque",slug:"muhammad-hoque",fullName:"Muhammad Hoque",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Management College of Southern Africa",country:{name:"South Africa"}}},{id:"428495",title:"Prof.",name:"Asyraf",middleName:null,surname:"Ab Rahman",slug:"asyraf-ab-rahman",fullName:"Asyraf Ab Rahman",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Malaysia Terengganu",country:{name:"Malaysia"}}},{id:"421024",title:"Prof.",name:"Harold Andrew",middleName:null,surname:"Patrick",slug:"harold-andrew-patrick",fullName:"Harold Andrew Patrick",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Jain University",country:{name:"India"}}},{id:"429650",title:"Dr.",name:"Jacqueline",middleName:null,surname:"Kareem",slug:"jacqueline-kareem",fullName:"Jacqueline Kareem",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Christ University",country:{name:"India"}}},{id:"421041",title:"Dr.",name:"Sunil",middleName:null,surname:"Kumar Ramdas",slug:"sunil-kumar-ramdas",fullName:"Sunil Kumar Ramdas",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Jain University",country:{name:"India"}}},{id:"421833",title:"Mr.",name:"Eugene",middleName:null,surname:"Owusu-Acheampong",slug:"eugene-owusu-acheampong",fullName:"Eugene Owusu-Acheampong",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Ghana",country:{name:"Ghana"}}},{id:"420823",title:"Prof.",name:"Gardênia da Silva",middleName:null,surname:"Abbad",slug:"gardenia-da-silva-abbad",fullName:"Gardênia da Silva Abbad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Brasília",country:{name:"Brazil"}}},{id:"437613",title:"MSc.",name:"Juliana",middleName:null,surname:"Legentil",slug:"juliana-legentil",fullName:"Juliana Legentil",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Brasília",country:{name:"Brazil"}}},{id:"239876",title:"Ph.D.",name:"Luciana",middleName:null,surname:"Mourão",slug:"luciana-mourao",fullName:"Luciana Mourão",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Salgado de Oliveira",country:{name:"Brazil"}}},{id:"421735",title:"Dr.",name:"elizabeth",middleName:null,surname:"addy",slug:"elizabeth-addy",fullName:"elizabeth addy",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421006",title:"Dr.",name:"Anna",middleName:null,surname:"Uster",slug:"anna-uster",fullName:"Anna Uster",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"470243",title:"Dr.",name:"Md Samim",middleName:null,surname:"Al Azad",slug:"md-samim-al-azad",fullName:"Md Samim Al Azad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"470244",title:"Dr.",name:"Slimane",middleName:null,surname:"Ed-dafali",slug:"slimane-ed-dafali",fullName:"Slimane Ed-dafali",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421011",title:"Dr.",name:"Afatakpa",middleName:null,surname:"Fortune",slug:"afatakpa-fortune",fullName:"Afatakpa Fortune",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"446057",title:"Mr.",name:"Okedare",middleName:null,surname:"David Olubukunmi",slug:"okedare-david-olubukunmi",fullName:"Okedare David Olubukunmi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421778",title:"Dr.",name:"Fatimah",middleName:"Saeed",surname:"AlAhmari",slug:"fatimah-alahmari",fullName:"Fatimah AlAhmari",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421065",title:"Ms.",name:"Euzália",middleName:null,surname:"do Rosário Botelho Tomé",slug:"euzalia-do-rosario-botelho-tome",fullName:"Euzália do Rosário Botelho Tomé",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421053",title:"Associate Prof.",name:"Ken",middleName:null,surname:"Kalala Ndalamba",slug:"ken-kalala-ndalamba",fullName:"Ken Kalala Ndalamba",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"421826",title:"Dr.",name:"Inusah",middleName:null,surname:"Salifu",slug:"inusah-salifu",fullName:"Inusah Salifu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null}]}},subseries:{item:{id:"40",type:"subseries",title:"Ecosystems and Biodiversity",keywords:"Ecosystems, Biodiversity, Fauna, Taxonomy, Invasive species, Destruction of habitats, Overexploitation of natural resources, Pollution, Global warming, Conservation of natural spaces, Bioremediation",scope:"